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Chronic inflammation in adipose tissue has been demonstrated to play an 
important role in the pathogenesis of insulin resistance. The infiltration of immune cells 
results in a significant increase of pro-inflammatory cytokines in adipose tissue that 
substantially affects adipocyte function. Lipocalin-2 (LCN2) is an adipocyte-secreted 
cytokine whose expression and secretion has been shown to be induced in obesity and 
insulin resistance in mouse and man. However, the underlying mechanisms have not 
been explored. Our studies indicate that interferon-gamma (IFNγ) and tumor necrosis 
factor-alpha (TNFα), two primary pro-inflammatory cytokines secreted from immune 
cells, can induce LCN2 expression and secretion from adipocytes both in vivo and in 
vitro. Mechanistic studies reveal that IFNγ modulates LCN2 expression via STAT1 and 
ERKs signaling pathways, while NF-κB and ERKs pathways mediate the actions of 
TNFα on LCN2 expression. Inhibition of ERKs activation attenuates the induction of 
LCN2 without significant effects on either the nuclear translocation or DNA binding 
activity of STAT1 and NF-κB. Further experiments show that pharmacological ERKs 
inhibition disrupts the serine phosphorylation of STAT1 and NF-κB p65 subunits, and 
reduces transactivation activity of both of these transcription factors. Moreover, we 
identified several STAT1 and NF-κB binding sites in both the murine and human LCN2 
promoters. Overall, these studies enhance our knowledge regarding the requirements 





CHAPTER 1. GENERAL INTRODUCTION 
1.1 Adipose Tissue, Obesity and Insulin Resistance 
Adipose tissue is an organ that consists of adipocytes and a stromal vascular 
fraction that contains preadipocytes, endothelial cells, and mesenchymal stem cells. 
Recent studies of adipose tissue have revealed that various immune cells can infiltrate 
into adipose tissue (1). Adipose tissue, skeletal muscle and liver are the three primary 
insulin sensitive tissues in the body. These tissues respond to insulin to regulate 
circulating glucose levels and maintain energy homeostasis. Insulin-stimulated glucose 
uptake in adipose tissue and skeletal muscle is essential for controlling blood glucose 
levels. In pathological conditions, insulin-sensitive tissues are often unresponsive to 
insulin because of disruptions in insulin signaling. This condition is referred to as insulin 
resistance, a major health risk that is associated with hypertension, cardiovascular 
disease and metabolic syndrome (reviewed in (2)). 
Adipocytes are one type of specialized cells in vertebrates. Adipocytes were 
initially known for their lipid storage function. However, studies in the past two decades 
have demonstrated that adipocytes play key roles in the regulation of energy 
homeostasis and systematic insulin sensitivity. Adipocytes have been demonstrated to 
have three important functions. Fat cells are the warehouses for lipid storage; they 
produce cytokines and hormones that modulate energy metabolism; and they are highly 
sensitive to insulin (reviewed in (3)). It is known that three important hormones, leptin 
(4), adiponectin (5) and resistin (6), are exclusively produced from adipocytes or 
adipose tissue in mice and humans. Leptin plays an essential role in the regulation of 
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food intake and energy balance (4). Adiponectin is critical for maintaining insulin 
sensitivity (5) and resistin is related to the pathogenesis of insulin resistance (6). 
Disruption of any one of the three primary functions of adipocytes can result in the 
disturbance of metabolic homeostasis and insulin resistance.  
Currently, most of our knowledge about adipocytes comes from studies 
performed in cultured cell lines. The most used adipocyte-like cell lines are the 3T3-L1 
and 3T3-F442A cells, both of which were cloned from the cultured murine embryonic 
fibroblast cell line 3T3. Howard Green and his colleagues at Harvard University 
separated the 3T3 cells that accumulated lipid after confluence to establish these two 
cell lines (7;8). Both 3T3-L1 and 3T3-F442A preadipocytes still have the capability to 
proliferate in growth media. However, once they are confluent, they are induced with a 
cocktail of hormones (isobutyl-methylxathine, dexamethasone and insulin) that 
promotes their exit from the cell cycle and differentiation into mature adipocytes (9). 
Obesity is a disease characterized by excess adipose tissue in the body that is 
caused by positive energy balance. Obesity has become a world-wide epidemic disease 
and affects more than 30% of adults in the United States (10). Plenty of evidence 
suggests that metabolically unhealthy adipose tissue in obese individuals plays a critical 
role in the occurrence of insulin resistance. Several metabolic pathways in adipocytes 
including glucose uptake, lipogenesis and lipolysis are significantly affected by insulin 
action. GLUT4 is an insulin-stimulated glucose transporter expressed in adipose tissue, 
skeletal muscle and heart. Under basal conditions, GLUT4 is stored in cytoplasmic 
vesicles. Upon stimulation with insulin, GLUT4 translocates to the cell membrane, and 
transports glucose molecules into cells (reviewed in (11)). However, in insulin-resistant 
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subjects, insulin-stimulated glucose uptake is impaired because of the inhibition of 
insulin signaling. A significant reduction of insulin-stimulated glucose uptake ultimately 
results in an increase of circulating glucose in insulin resistant and diabetic subjects 
(reviewed in (12)). 
1.2 Pro-inflammatory Cytokines in Adipose Tissue 
Pro-inflammatory cytokines are important immune response mediators that can 
induce both acute and chronic inflammation. These cytokines are largely secreted from 
immune cells, including macrophages, cytotoxic T cells and natural killer cells (13;14). 
Prior to studies that revealed the connection between inflammation and insulin 
resistance in adipose tissue, there was substantial evidence to indicate that pro-
inflammatory cytokines can induce insulin resistance (15). In 2003, chronic inflammation 
and infiltration of immune cells in adipose tissues was shown to be a critical player in 
obesity-related insulin resistance (1;16). It was demonstrated that macrophages could 
infiltrate into white adipose tissues (WAT) of obese subjects, and affect the 
physiological functions of adipose tissues (1). The pro-inflammatory cytokines secreted 
from immune cells are substantially increased in adipose tissue of obese and diabetic 
animal models (1;16). Previous studies have reported that the pro-inflammatory 
cytokines affect the three primary functions of adipocytes. TNFα and IFNγ have been 
shown to inhibit lipogenesis in adipocytes (17;18). Several pro-inflammatory cytokines, 
including TNFα (15), IFNγ (19) and IL-1β (20), have been known to disrupt insulin 
signaling and induce insulin resistance. Pro-inflammatory cytokines also have the 
capability to affect gene expression in mature adipocytes. Expression of PPARγ and 
adiponectin, two important modulators of insulin sensitivity, are reduced by pro-
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inflammatory cytokines (21;22). Also, pro-inflammatory cytokines induce the expression 
and secretion of chemokines (23-25), which recruit more immune cells into adipose 
tissues. Hence, the actions of pro-inflammatory cytokines affect the physiological 
functions of adipocytes and adipose tissue. 
TNFα 
Tumor necrosis factor-alpha (TNFα) is an important pro-inflammatory cytokine 
produced from monocytes and macrophages (13). TNFα is well known for its ability to 
mediate immune response (26), apoptosis (27) and autophagy (28). In addition, TNFα 
can be produced from macrophages that infiltrate into adipose tissue (1;29). Expression 
of TNFα significantly increases in adipose tissue of obese and insulin-resistant 
individuals (30;31) due to its production in adipose tissue macrophages. The elevation 
of TNFα is attenuated by decreases of body weight, which also increases insulin 
sensitivity (30).  
As the first cytokine that was recognized to induce insulin resistance in 
adipocytes, TNFα was shown to repress transcription of glucose transporter GLUT4 (32) 
and expression of insulin receptor (IR) and insulin receptor substrate-1 (IRS-1) in 
cultured 3T3-L1 adipocytes (33). Tyrosine phosphorylation of IR and IRS-1 is required 
for activation of insulin signaling in adipocytes (34), while serine phosphorylation of IRS-
1 prevents activation of insulin signaling (35). TNFα has been reported to disrupt insulin 
signaling via inhibiting insulin-stimulated tyrosine phosphorylation of IR and IRS-1 
(15;36) and inducing serine phosphorylation of IRS-1 (35;37) in cultured adipocytes. 
Peroxisome proliferator-activated receptor-gamma (PPARγ) (38) and adiponectin (39) 
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are two well-known positive regulators of insulin sensitivity. The expression of both 
PPARγ (22) and adiponectin (40) has been found to be suppressed by TNFα. In 
addition, TNFα has been demonstrated to repress PPARγ activity via inducing cyclin-
dependent kinase 5 (CDK5)-mediated phosphorylation on Serine 273 residue (41). In 
vivo studies have reported that TNFα administration impairs insulin sensitivity and 
reduces insulin-stimulated glucose uptake in humans (42;43). Neutralization of TNFα in 
obese fa/fa rats significantly increases tyrosine phosphorylation of IR and IRS-1 (44). To 
further clarify the roles of TNFα in vivo, TNFα knockout mice were created to study the 
influence of TNFα deficiency on insulin sensitivity. TNFα-deficient DIO (diet induced 
obesity) and ob/ob (leptin deficient) mice exhibited a significant improvement of insulin 
sensitivity compared to normal DIO and ob/ob mice (45). The inhibition of insulin 
signaling in both DIO and ob/ob mice was attenuated by the deficiency of TNFα (45).  
Both in vitro and in vivo studies provide evidence that TNFα contributes to the 
occurrence of obesity-related insulin resistance.  
IFNγ 
Interferon-gamma (IFNγ) is the only member of the type 2 interferon family and 
has important roles in immune responses to viral infection (46). IFNγ can be secreted 
from lymphocytes, NK cells, B cells, and antigen-presenting cells (APCs) to activate 
cell-specific immunity and cytotoxic immunity during viral infection (14). In obese and 
insulin resistant conditions, IFNγ is produced and secreted from the immune cells that 
infiltrate into adipose tissue (47). A previous study has shown that high-fat diet 
increases IFNγ production in adipose tissues (48). Human studies have revealed that 
IFNγ is highly up-regulated in obese individuals (49).  
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In 1998, hyperglycemia and insulin resistance was reported in humans with IFNγ 
therapy (50). Studies of adipocytes provided evidence that IFNγ plays essential roles in 
the occurrence of insulin resistance. IFNγ administration impairs insulin-stimulated 
glucose uptake in both murine and human adipocytes (19;51). Insulin signaling was 
inhibited by IFNγ treatment via reducing expression of IR, IRS-1, GLUT4 and 
phosphorylation of Akt (51). In human adipocytes, the expression of PPARγ and 
adiponectin is also inhibited by IFNγ treatment (51;52). Mechanistic studies in our group 
demonstrated that IFNγ reduced PPARγ levels in 3T3-L1 adipocytes by inhibiting 
PPARγ expression (53) and inducing ubiquitin-proteasome dependent degradation of 
PPARγ (54). Also, IFNγ has been reported to suppress normal lipid accumulation and 
adipocyte development (55;56). In mature adipocytes, IFNγ was also found to inhibit 
lipoprotein lipase activity and lipid storage (18). The prevention of lipid storage in 
adipocytes and decreased expandability of adipose tissue could result in ectopic lipid 
storage in other tissues, such as the liver. Ectopic lipid storage is considered to 
contribute to the pathogenesis of insulin resistance (57). Consistent with cell culture 
experiments, animal studies also suggest a role of IFNγ in the pathogenesis of insulin 
resistance. IFNγ deficiency attenuates inflammation in adipose tissues and modestly 
improves insulin sensitivity in DIO mice (58).  
Other pro-inflammatory cytokines 
As major pro-inflammatory cytokines, there is substantial evidence that TNFα 
and IFNγ have important effects on adipose tissue in obese and insulin resistant 
subjects. However, besides TNFα and IFNγ, there are other pro-inflammatory cytokines 
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that can also modulate of insulin sensitivity. These include interleukin-6 (IL-6), 
plasminogen activator inhibitor-1 (PAI-1), and interleukin-1β (IL-1β). 
Interleukin-6 (IL-6) is a member of the gp130 cytokine family. It is estimated that 
10-35% of plasma IL-6 is produced from adipose tissue (59). The expression and 
secretion of IL-6 is highly induced in adipocytes of insulin-resistant individuals (60). 
Circulating IL-6 is significantly increased in obesity and insulin resistance (31). However, 
the effects of IL-6 on insulin sensitivity are still controversial. Studies in cultured 
adipocytes reported that chronic treatment of IL-6 inhibits expression of insulin signaling 
proteins IR, IRS-1, glucose transporter GLUT4 (61), and proteins associated with insulin 
sensitivity such as adiponectin (62) and PPARγ (63). Another study showed that IL-6 
up-regulated expression of the inflammatory marker monocyte chemotactic protein-1 
(MCP-1) (64). A study in humans indicated that IL-6 administration significantly 
increases plasma glucose level in a dose-dependent manner (65). Animal experiments 
have demonstrated that chronic IL-6 treatment at pathological concentrations in obesity 
could inhibit the phosphorylation of IR and IRS-1&2 in liver (66), but had no effect on 
insulin signaling in adipose tissue of mice (67). Yet, other studies demonstrated positive 
effects of IL-6 on insulin sensitivity. In skeletal muscle, IL-6 expression has been 
reported to be induced by exercise (68). IL-6 treatment increases AMPK activity and up-
regulates expression of AMPK target genes (69). AMPK activity is impaired in skeletal 
muscle and adipose tissue of IL-6 knockout mice (69). Other studies showed that high-
fat diet (HFD) fed IL-6-deficient mice had more severe hepatic insulin resistance and 
inflammation than wild-type mice fed with HFD (70). Hence, the role of IL-6 in insulin 
action is confusing and controversial. 
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Plasminogen activator inhibitor-1 (PAI-1) was identified for its roles in fibrosis 
during inflammation. PAI-1 is mainly expressed in the endothelium, but can also be 
produced and secreted from both preadipocytes (71) and mature fat cells (72;73). 
Circulating levels of PAI-1 are positively related to body mass index (BMI) (74), and 
significantly elevated in subjects with metabolic syndrome (75) and insulin resistance 
(76). PAI-1 deficient mice are protected from HFD-induced insulin resistance (77). The 
decrease of PPARγ and adiponectin expression that normally occurs in HFD-fed mice 
was attenuated by PAI-1 knockout (77). Plasma free fatty acid (FFA) and TNFα levels 
were also down-regulated by PAI-1 deficiency (78). Although the signaling pathway 
utilized by PAI-1 is still uncovered, there is substantial evidence that PAI-1 is a novel 
mediator of obesity-induced insulin resistance.  
Interleukin-1β (IL-1β) is mainly produced from monocytes, macrophages and 
dendritic cells. IL-1β plays important roles in the occurrence of chronic inflammatory 
diseases (79). Expression of IL-1β in adipose tissue is elevated in obesity-related insulin 
resistance (80). In cultured adipocytes, IL-1β has been found to inhibit insulin-stimulated 
glucose uptake and lipogenesis via attenuating insulin-induced phosphorylation of IR 
and IRS-1 (20). Expression of glucose transporter GLUT4 (81) and adiponectin (52) is 
also repressed by IL-1β treatment.  Animal studies have shown that IL-1β administration 
increases hepatic glucose production, decreases glucose deposit, and induces insulin 
resistance (82). Collectively, these results suggest that IL-1β also plays a role in insulin 




1.3 Signaling Pathways in Adipocytes 
JAK-STAT Signaling Pathway 
The Janus kinase (JAK)-signal transducers and activators of transcription (STAT) 
signaling pathway is widely utilized by hormone and cytokine receptors that do not have 
enzymatic activity. The interaction between a ligand and receptor activates JAK. 
Activated JAK binds to the receptor and phosphorylates the receptor on tyrosine 
residues. The Src-homology 2 (SH2) domain within the STATs recognize and associate 
with phosphorylated tyrosines within the cytosolic portion of the receptor. Next, the 
STAT is phosphorylated by the active JAK. The tyrosine phosphorylation induces 
dimerization of STATs and dimerized STATs translocate to the nucleus and interact  
with promoters to modulate gene expression (reviewed in (83)). There are four 
members of the JAK family: Jak1, Jak2, Jak3 and Tyk2, and seven members of the 
STAT family: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6. However, 
only STAT1, 3, 5A, 5B and 6 are expressed in mature adipocytes (reviewed in (84)). 
Previous studies have shown that expression of STAT1, 5A and 5B significantly 
increases during adipogenesis (85;86). STAT3, 5A and 5B have been reported to play 
important roles in the adipogenic process. SiRNA-mediated knockdown of STAT3 
inhibits adipocyte development (87). STAT5 proteins are also are essential for 
adipogenesis. STAT5 antisense oligonucleotides inhibit growth hormone (GH)-induced 
adipogenesis (88) and constitutively active STAT5 has the capability to induce 
differentiation of preadipocytes (89). Ectopic expression of STAT5A not only induces 
differentiation of 3T3-L1 preadipocytes (90), but also promotes adipogenesis in non-
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precursor cell lines (91). In vivo experiments have demonstrated that ectopic expression 
of STAT5A can confer adipogenesis in cells that would not normally become adipocytes 
(92). Also, STAT5-deficient mice have much smaller fat pads (93) and STAT5 signaling 
pathways mediate the GH-induced expression of PPARγ in 3T3-L1 and C3H10T1/2 
cells (94). 
Previous studies have identified activators of JAK-STAT signaling pathways in 
adipocytes. GH and prolactin (PRL) have been shown to activate STAT5 to modulate 
gene expression (94-99). Studies from the Stephens laboratory have demonstrated that 
acyl-CoA oxidase (AOX) (100) and aP2 (101) are regulated by GH, while fatty acid 
synthase (FAS) (102) and pyruvate dehydrogenase kinase 4 (PDK4) (98) are 
modulated by both GH and PRL. Our unpublished data also shows that the expression 
of adiponectin is inhibited by GH in 3T3-L1 adipocytes, and that the STAT5 signaling 
pathway mediates this response. In addition to these anterior pituitary hormones, a 
variety of cytokines also utilize the JAK-STAT signaling pathway in mature adipocytes. 
The pro-inflammatory cytokine IFNγ modulates expression of lipoprotein lipase (LPL) 
via activation of the STAT1 signaling pathway (103). Gp130 cytokines, including 
cardiotrophin-1 (104;105), interleukin-11 (106), and leukemia inhibitory factor 
(95;107;108) have been shown to utilize STAT1 and STAT3 signaling pathways in fat 
cells. 
NF-κB Signaling Pathway 
The nuclear factor-κB (NF-κB) signaling pathway was originally identified in 
immune cells, and is comprised of both positive and negative regulators. In basal 
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conditions, IκB associates with NF-κB and inhibits its activity. Upon stimulation, the 
interaction between ligand and receptor activates NF-κB signaling by inducing the 
phosphorylation of IκB kinase (IKK). Phosphorylated IKK is able to phosphorylate IκB. 
Phosphorylation results in the dissociation of IκB from NF-κB, and IκB is then 
ubiquitinated and degraded. The active NF-κB translocates to the nucleus and regulates 
the expression of target genes (reviewed in (109)). The five members of the NF-κB 
family, p50, p52, p65 (RelA), c-Rel and RelB, share a homologous N-terminus that 
contains a Rel homology domain (RHD). RHD is required for the dimerization and DNA 
binding activity of NF-κB. RelB, c-Rel and p65 have their transcription activation domain 
(TAD) at the C-terminus, while p50 and p52 do not have a TAD. P50 and p52 need to 
associate with coactivators to induce gene expression (reviewed in (109)). 
The NF-κB signaling pathway is widely used by pro-inflammatory cytokines, 
including TNFα, IL-1β and LPS, which are potent inducers of insulin resistance in 
adipose tissue (reviewed in (110)). NF-κB has been demonstrated to mediate TNFα-
induced expression of chemokines in adipocytes (111). The increase of chemokines, 
such as CCL5 (24), CXCL5 (23) and CXCL14 (25), likely contributes to the recruitment 
of immune cells into adipose tissues and the impairment of insulin sensitivity. The 
suppression of PPARγ expression by TNFα treatment is also mediated by activated NF-
κB signaling pathway (22). 
ERK Signaling Pathway 
Extracellular signal-regulated kinase (ERK) belongs to the family of mitogen-
activated protein kinases (MAPKs). ERKs are well known for their important roles in 
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regulating cell proliferation and oncogenesis. In ERKs signaling pathways, the GTPase 
Ras can be activated by receptor tyrosine kinase (RTK)-Grb2-SOS axis. Activated Ras 
induces the activation of Raf, which phosphorylates and activates MEK1/2. Then, 
activated MEK1/2 has the capability to phosphorylate and activate ERK1/2. ERKs are 
serine/threonine kinases. The activated ERKs regulate activities of important 
transcription factors via phosphorylation of their seine and/or threonine residues 
(reviewed in (112)). Previous studies have demonstrated that activation of the ERKs 
signaling pathway induces adipogenesis through up-regulating expression of PPARγ 
and C/EBPα, both of which are required for adipogenesis (113). As a universal signaling 
pathway adopted by cytokines, ERKs signaling mediates many effects on gene 
expression. Studies in 3T3-L1 adipocytes indicate that activation of ERKs mediates 
TNFα-induced insulin resistance (114). Activation of ERKs signaling is responsible for 
the TNFα-induced suppression of expression and phosphorylation of IR, IRS1, and 
IRS2 (114). Studies from the Stephens laboratory have demonstrated that IFNγ-induced 
ERKs activation mediates phosphorylation of PPARγ at Serine112, which facilitates the  
degradation of PPARγ (54). Besides IFNγ and TNFα, other cytokines/hormones, 
including GH and gp130 cytokines, have been found to activate ERKs signaling 
pathway in mature adipocytes (97;115). 
1.4 Lipocalin-2 
Lipocalin-2 (LCN2) belongs to the lipocalin family, a group of proteins that 
transport small and hydrophobic molecules in circulation (116). LCN2 was first identified 
for its interaction with matrix metalloproteinase 9 (MMP-9). LCN2 is able to stabilize 
MMP-9 and protect it from degradation (117). Follow-up studies indicate that LCN2 
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plays important roles in the innate immune response by limiting bacterial growth 
(118;119). More functional studies have revealed that LCN2 has the ability to promote 
migration of vascular smooth muscle cells (120) and induce epithelial-mesenchymal 
transition (121). A recent study also demonstrates that LCN2 is increased in chronic 
kidney diseases and may participate in pathogenic processes (122). Studies in the 
central nervous system have shown that LCN2 expression is elevated by viral infection 
(123). It is likely that LCN2 has a variety of different functions in different tissues.  
Previous research has shown that LCN2 can be produced and secreted from 
mature adipocytes (124). LCN2 expression significantly increases during adipogenesis 
(125). Animal studies have reported that LCN2 expression is substantially induced in 
ob/ob and db/db mice (125). In human studies, circulating LCN2 is positively related 
with adiposity, blood triglyceride, blood glucose and insulin resistance (126;127), and 
negatively associated with high-density lipoprotein cholesterol (127). Previous studies 
have shown that some inducers of insulin resistance, IL-1β (128), lipopolysaccharide 
(LPS) (129) and glucocorticoids (130) can up-regulate LCN2 expression. Also, the 
insulin sensitizer thiazolidinedione inhibits LCN2 expression. 
Although it has been demonstrated that LCN2 expression is increased in obesity 
and insulin resistance (125), the mechanisms involved in this process and the functions 
of LCN2 in insulin resistance are unclear. LCN2 administration to 3T3-L1 adipocytes 
has been shown to increase the expression of PPARγ and adiponectin and attenuate 
the inhibitory effect of TNFα on insulin-stimulated glucose uptake (131). However, 
another study showed that shRNA-mediated knockdown of LCN2 improves insulin 
sensitivity and insulin-stimulated glucose uptake in adipocytes (125). To clarify the roles 
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of LCN2 in the pathogenesis of insulin resistance, LCN2 knockout mice were created. 
However, the LCN2 null mice created and studied by different groups showed 
completely different phenotypes. Study from Chen’s lab reported that LCN2 deficiency 
results in the impairment of insulin sensitivity (132), while another group found that 
LCN2-deficient mice are protected from obesity-related insulin resistance (133). Later, a 
third paper published by Rosen’s lab showed that LCN2 knockout does not substantially 
affect obesity-induced insulin resistance (134). Although the functions of LCN2 in 
modulating insulin sensitivity are still unknown, all the studies provide evidence that 
LCN2 is induced in adipose tissue in conditions of insulin resistance. There is also 
evidence that LCN2 deficiency enhances the HFD-induced expansion of inguinal fat 
(135), and  LCN2 administration increases energy expenditure in vivo and up-regulates 
expression of genes participating in β-oxidation to increase fatty acid oxidation in 
adipocytes (136). 
1.5 Research Focus 
Obesity and obesity-related metabolic diseases are a worldwide epidemic and 
health risk. Adipocyte and adipose tissue play essential roles in the pathogenic 
processes associated with metabolic disease states. In our studies, we examined LCN2 
expression in adipocytes in vitro and in vivo. These results reveal the mechanisms 
involved in the regulation of LCN2 in obesity and insulin resistance. The results 
demonstrated that IFNγ and TNFα, the two major pro-inflammatory cytokines, induce 
LCN2 expression and secretion both in vitro and in vivo. These studies suggest that 
pro-inflammatory cytokines from immune cells in adipose tissue affect the endocrine 
functions of adipocytes in obese and insulin resistant conditions. Studying the signaling 
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pathways utilized by the pro-inflammatory cytokines has also revealed how adipocyte 
function is influenced by chronic inflammation. In our studies, we demonstrate that the 
induction effects of IFNγ are mediated by STAT1 and ERKs signaling pathways and the 
TNFα effects are mediated via NF-κB and ERKs signaling pathways in mature 
adipocytes. Moreover, our novel results have revealed that ERKs signaling pathways 
interact with STAT1 and NF-κB pathways via modulation of STAT1 and p65 serine 
phosphorylation. In silico, in vitro, and in vivo studies of the murine and human LCN2 
promoters have identified conserved transcription factor binding sites. These studies 
have revealed the mechanisms involved in LCN2 expression in obesity and insulin 
resistance and have increased our knowledge of signaling pathways utilized by pro-











CHAPTER 2. STAT1, NF-κB AND ERKS PLAY A ROLE IN THE INDUCTION OF 
LIPOCALIN-2 EXPRESSION IN ADIPOCYTES 
 
2.1 Introduction 
Adipose tissue is a major insulin sensitive tissue that plays key roles in regulating 
energy metabolism and insulin sensitivity (3;137;138). Chronic inflammation and 
infiltration of immune cells in adipose tissues has been demonstrated to modulate 
adipocyte function and result in alterations of hormone secretion and insulin sensitivity 
(1;16). TNFα and IFNγ are important pro-inflammatory cytokines that are known to be 
secreted from immune cells that infiltrate into adipose tissues (1;44;139). These 
immune cells have the ability to induce insulin resistance in both cultured adipocytes 
and experimental animal models (35;44;140;141). IFNγ signals via activating Janus 
kinase (JAK)-signal transducer and activator of transcription 1 (STAT1) signaling 
pathway and extracellular signal-regulated kinases (ERKs) mediated signaling pathway 
(141;142). TNFα utilizes various signaling pathways and can stimulate both nuclear 
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 Lipocalins are a family of proteins that bind and transport small or hydrophobic 
molecules with conserved ligand binding sites (116). As a member of the lipocalin family, 
lipocalin-2 (LCN2), also called neutrophil gelatinase-associated lipocalin (NGAL), was 
initially discovered as a matrix metalloproteinase 9 (MMP-9) binding protein that 
attenuated MMP-9 degradation (117). Studies have shown that LCN2 increases during 
exposure to invading bacteria (145) and can be bound to bacterial siderophores to limit 
bacterial growth by reducing iron uptake (118;119). More recent research has revealed 
that LCN2 is secreted from mature adipocytes (124). Expression of LCN2 is significantly 
up-regulated in conditions of insulin resistance and type 2 diabetes (T2DM) (125). 
Human studies indicate that circulating LCN2 positively correlates with adiposity, 
triglyceride, blood glucose level, insulin resistance, and is negatively related to high-
density lipoprotein cholesterol (126;127). However, the roles of LCN2 in the pathology 
of adipose tissue insulin resistance are still unclear. There is evidence that LCN2 can 
induce the expression of PPARγ and adiponectin (131) and that administration of LCN2 
attenuates the inhibitory effect of TNFα on insulin-stimulated glucose uptake (131). 
However, other data indicates that knockdown of LCN2 improves insulin action in 
adipocytes (125). In order to clarify the functions of LCN2 in whole body insulin 
sensitivity, LCN2 knockout mice have been generated by several labs. However, the 
results of these studies have further clouded our understanding of the functions of LCN2 
and the topic is even more controversial. In one study, global LCN2 deficiency caused 
dyslipidemia, fatty liver and insulin resistance (132). On the contrary, a separate study 
indicated that LCN2 null mice had improved aging and obesity-mediated insulin 
resistance (133), supporting the notion that the lack of LCN2 is metabolically favorable.  
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The most recent characterization of LCN2 deficient mice indicates that LCN2 deficiency 
did not have a significant effect on age or obesity-induced insulin resistance (134). 
Collectively, these studies suggest that the roles of LCN2 in modulating insulin 
sensitivity are still unclear. Nonetheless, there are numerous studies and clear and 
convincing evidence to demonstrate that modulation of LCN2 in mice and humans 
significantly affects insulin sensitivity. Our studies have focused on understanding the 
regulation of LCN2 expression by factors that contribute to the pathogenesis of insulin 
resistance.    
 To enhance our understanding of LCN2 in obesity and insulin resistance, we 
performed mechanistic studies to examine how LCN2 expression is induced in 
adipocytes. Our results demonstrate that the increase of LCN2 expression is mediated 
by pro-inflammatory cytokines that are present in adipose tissue in conditions of insulin 
resistance in mice and man. We observed that LCN2 expression and secretion was 
induced by IFNγ and TNFα in both murine 3T3-L1 adipocytes and human subcutaneous 
adipocytes. STAT1 and ERKs 1 and 2 signaling pathways mediated the effects induced 
by IFNγ and the effects of TNFα on LCN2 expression were mediated by both NF-κB and 
ERKs 1 and 2 signaling pathways. Our studies of the murine LCN2 promoter identified 
five STAT1 binding sites and one NF-κB binding site. Inhibition of ERKs signaling 
pathway attenuated the stimulatory effects of both IFNγ and TNFα on LCN2 expression. 
Inhibition of ERKs 1 and 2 reduced the activity of STAT1 and NF-κB without having any 
significant effects on the nuclear localization or DNA binding activity of these pro-
inflammatory transcription factors. These mechanistic studies provide insight into the 
modulation of LCN2 that occurs during insulin resistance.  
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2.2 Experimental Procedures 
Cell culture 
Murine 3T3-L1 preadipocytes were grown to 2 days after confluence in 
Dulbecco's Modified Eagle's Media (DMEM) with 10% bovine serum. Media was 
changed every 48 h. 0.5 mmol/l 3-isobutyl-methylxanthine, 1 μmol/l dexamethasone, 
and 1.7 μmol/l insulin (MDI) cocktail were used to induce preadipocytes differentiation in 
DMEM containing 10% fetal bovine serum (FBS). After 48 h, the media was replaced by 
DMEM with 10% FBS. For serum deprivation, media was change to DMEM containing 
0.3% BSA for 16–20 h before treatment. DMEM was purchased from Sigma. Bovine 
and FBS were purchased from Hyclone. Human subcutaneous adipocytes in 12-well 
plates were purchased from Zen-Bio. Cells were serum-deprived for 16 h before 
treatment. Recombinant mouse and human IFNγ were purchased from R&D Systems. 
Recombinant mouse and human TNFα were purchased from Gibco. Actinomycin D was 
purchased from Sigma. 
Preparation of whole cell extracts 
Cell monolayers were harvested in a non-denaturing IP buffer that contained 
10 mmol/l Tris (pH 7.4), 150 mmol/l NaCl, 1 mmol/l EGTA, 1 mmol/l EDTA, 1% Triton X-
100, 0.5% Nonidet P-40, with protease inhibitors 1 μmol/l phenylmethylsulfonyl fluoride, 
1 μmol/l pepstatin, 50 mU trypsin inhibitory aprotinin, 10 μmol/l leupeptin, and 
phosphatase inhibitor 2 mmol/l sodium vanadate. The cells were scraped off the plates 
and the extract was passed through a 20 g needle three times. The extract was 
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centrifuged at 9500gfor 10 min at 4 °C. Supernatants were collected and analyzed with 
BCA (Pierce) to quantify protein content of whole cell extract. 
RNA analysis 
Total RNA was isolated from cell monolayers with RNeasy mini kit (Qiagen). 
10 μl of RNA extract was used for reverse transcription PCR. cDNA was analyzed by 
delta delta ct real-time PCR with SYBR supermix reagent (Takara) and Applied 
Biosystem 7900HT system. Cyclophilin A was used as endogenous control. Following 
primers were used for the real-time PCR: mLCN2 forward TGCAAGTGGCCAC 
CACGGAG and reverse GCATTGGTCGGTGGGGACAGAGA; mCyclophilin A forward 
CCACTGTCGCTTTTCGCCGC and reverse TGCAAACAGCTCGAAGGAGACGC. 
3T3-L1 adipocyte fractionation 
Cell monolayers were harvested in nuclear homogenization buffer containing 
20 mmol/l Tris (pH 7.4), 10 mmol/l NaCl, 3 mmol/l MgCl2, 1 μmol/l dithiothreitol, with 
protease inhibitors listed above and 2 mmol/l sodium vanadate. Nonidet P-40 was 
added to final concentration of 0.15%. Cells were homogenized with 18 strokes in a 
Dounce homogenizer and centrifuged at 500g for 5 min. Supernatants were transferred 
to another tube as cytosolic extract. The precipitated nuclear pellets were resuspended 
in one-half volume of nuclear homogenization buffer and were centrifuged as before. 
The supernatant was removed and discarded. The majority of the pellet (intact nuclei) 
was resuspended in nuclear extraction buffer containing 20 mmol/l HEPES (pH 7.9), 
150 mmol/l NaCl or 420 mmol/l NaCl, 1.5 mmol/l MgCl2, 0.2 mmol/l EDTA, 1 μmol/l 
dithiothreitol, 25% glycerol and the with protease inhibitors listed above with 2 mmol/l 
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sodium vanadate. Resuspended nuclei were passed three times through a 20G needle 
every 10 min and extracted for 30 min on ice. The samples were centrifuged at 9500g at 
4 °C for 10 min. The resulting supernatant was a nuclear extract. 
Gel electrophoresis and immunoblotting 
Proteins were separated in 7.5% or 10% polyacrylamide gels containing SDS, 
and transferred to nitrocellulose membrane (Bio-Rad) in 25 mmol/l Tris, 192 mmol/l 
glycine, and 20% methanol. After transfer, the membrane was blocked in 4% milk for 
1 h at room temperature, and incubated with primary antibody overnight at 4 °C. Results 
were visualized with horseradish peroxidase-conjugated secondary antibodies (Jackson 
ImmunoResearch Laboratory) and enhanced chemiluminescence (Pierce). STAT1 
antibody was purchased from Cell Signaling Technology. LCN2 antibody was from R&D 
System. STAT5A, p65, ERK1/2 antibodies were from Santa Cruz technology. 
Adiponectin antibody was from Thermo-Pierce. STAT1pY antibody was from Millipore. 
Active ERK1/2 antibody was from Promega. 
Electrophoretic mobility shift analysis 
Double-stranded oligonucleotides were annealed by heating single-stranded 
oligonucleotides (sequences shown in Table 1 and Table 2) in 95 °C water bath and 
gradually cooling to room temperature. 4 μg double-stranded oligonucleotides were 
labeled with 20 μCi [α-P32]dCTP (PerkinElmer) and 1 μl of each 5 mM dATP, dTTP, 
dGTP using Klenow fragment. The mix was incubated for 15 min at 30 °C. The reaction 
was stopped by adding 1 μl of 0.5 M EDTA. Labeled double-stranded oligonucleotides 
were purified with illustra MicroSpin G-25 Columns (GE Healthcare) according to 
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manufacturer's instructions. Radioactivity of labeled oligonucleotides was determined by 
scintillation counting. Nuclear extracts were incubated with the labeled oligonucleotides 
for 30 min on ice. The samples were separated in a pre-run (30 min, 200 V at 4 °C) 6% 
acrylamide/bisacrylamide TBE gel. Nuclear extracts were pre-incubated with 1 μg 
antibody (STAT1, STAT3, STAT5A, STAT5B or p65 from Santa Cruz Technology) for 
1 h at room temperature for supershift assay. The gels were run at 200 V for ~3.5 h, 
dried at 80 °C for 45 min with vacuum, and then exposed to Eastman Kodak Co. 
BioMax MS film with a Kodak BioMax high energy intensifying screen. 





































Table 2. Mutant oligos for EMSA 
















ChIP assay was performed with SimpleChIP® Enzymatic Chromatin IP Kit (Cell 
Signaling Technology) according to the protocol supplied by company. Cells were 
serum deprived overnight in DMEM containing 0.3% bovine serum. Cells were treated 
with IFNγ or TNFα for 30 min in the presence or absence of UO129, an ERK inhibitor 
(Promega). Adipocytes were cross-linked with formaldehyde and glycine. Chromatin 
extracts were prepared after sonication of harvested cells. Immunoprecipitation was 
performed with specific STAT1 (Cell Signaling Technology) or p65 (Cell Signaling 
Technology) antibodies. Rabbit normal IgG was used as a negative control. Purified 
DNA was quantified by real-time PCR with following primers: -266 forward 
GTGGACAGGCAGTCCAGATCTGAG and reverse AAGATTTCTGTCCCTCTCTCCC 
CC; -619 forward CTGTTCCTGTAAATGGCAGTGGGG and reverse GGGTGAGCAAG 
CTGAGAGTGAATG; -676 forward TAAGGACTACGTGGCACAGGAGAG and reverse 
GAAGTGTCCAATACCTTGAGCCCC; -1014 forward GCTTCTGCCCAAAGTAACTGG 
AGT and reverse TAAGGACTGCAACCTCGGTGTCAT; -1822 forward CTGCCC 
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TGAGTGTTGGGTTCAAAG and reverse CTGGGGATGTAGCTCTCTGGTGTT; -3171 
forward TAGTCCTGCATTCAGTTTGCAGGC and reverse ACCCAGGTCCAATCCA 
CATGAAGA. 500 nM of each primer and 2 μl ChIP product were used with SYBR green 
supermix and ROX buffer (Takara) in 20 μl PCR reaction. Percentage of input was 
calculated by the formula:  
Percentage of input=2%×2(C[T] 2% input sample−C[T] IP sample). 
Plasmid constructs 
A 3470 bp-fragment of LCN2 promoter (−3358 to 112) was cloned from genomic 
DNA of mouse liver. The fragment was amplified with following primers: forward: 
GATCGGTACCAAAGGGCTCTCCAGGTTCTC; reverse: GATCGATATCGGCAGGG 
ATCAAGTTCTGAG. Nucleotides were added to the 5′ ends of each primer so that the 
forward primer could be digested by KpnI and the reverse primer by EcoRV for ligation 
into the pGL4.27 vector to create pGL4.27-LCN2pro. Plasmids were sequenced for 
verification of nucleotide sequence. 
Plasmid transfection and luciferase reporter assays 
Mature 3T3-L1 adipocytes in six-well plates were transfected with 2 μg pGL4.27-
LCN2pro by using Dharmacon turboFect reagent (ThermoScientific). 2 μg pRL-
TK/renilla vector was co-transfected to control transfection efficiency. After 24 h, the 
adipocytes were pretreated with UO126 for 30 min and that was followed by IFNγ or 
TNFα treatment for 24 h. Cell lysis was prepared with passive lysis buffer. Luciferase 
activity was measured with the Dual Luciferase Reporter System (Promega). Relative 
luciferase units were calculated by dividing firefly luciferase activity values by renilla 
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luciferase activity. Each condition was performed in triplicate and on three independent 
batches of adipocytes. 
2.3 Results 
LCN2 expression and secretion is up-regulated by pro-inflammatory cytokines 
Previous studies showed that LCN2 is expressed in adipocytes and increased in 
obese and diabetic subjects (125). However, the mechanisms involved in the induction 
of LCN2 expression are unknown. In our studies, we observed that both IFNγ and TNFα 
induced the expression and secretion of LCN2. Whole cell extracts and media samples 
were prepared from 3T3-L1 adipocytes that were untreated or treated for 24, 48, or 72 
hours. As shown in Figures 2.1 and 2.2, LCN2 expression and secretion were induced 
by IFNγ and TNFα treatment within 24h. After 24h IFNγ treatment, the cellular levels of 
LCN2 were induced and remained high. However, the effect of TNFα on LCN2 levels 
increased over time. Since adiponectin expression and secretion is attenuated by both 
IFNγ and TNFα (19;21), we used it as control to assess the effectiveness of cytokine 
treatment. STAT5A was used as a loading control. As expected, cytokine treatment 
decreased adiponectin levels, but did not effect STAT5A expression. To determine if the 
observed effects were dependent on new transcription, we pretreated 3T3-L1 
adipocytes with Actinomycin D for 30 min, followed by a IFNγ or TNFα treatment. As 
shown in Figure 2.3, TNFα is a more potent inducer of LCN2 mRNA than IFNγ. In 
addition, the presence of Actinomycin D inhibited the ability of both inflammatory 
mediators to induce LCN2 mRNA expression.  
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Figure 2.1. IFNγ and TNFα induce LCN2 expression and secretion in 3T3-L1 adipocytes. 
Mature 3T3-L1 adipocytes were chronically treated with 100ng/ml IFNγ. Media was 
collected and whole cell extract was harvested at indicated time. Time 0 indicates no 
treatment. 250μg protein from media samples and 150μg of whole cell extracts were 
subjected to western blot analysis.  
 
              
Figure 2.2. IFNγ and TNFα induce LCN2 expression and secretion in 3T3-L1 adipocytes.  
Mature 3T3-L1 adipocytes were chronically treated with 0.5nM TNFα. Media was 
collected and whole cell extract was harvested at indicated time. Time 0 indicates no 
treatment. 250μg protein from media samples and 150μg of whole cell extracts were 






Figure 2.3. IFNγ and TNFα induce LCN2 expression and secretion in 3T3-L1 adipocytes.  
Adipocytes were pretreated with 5μg/ml Actinomycin D for 30min, and then treated with 
IFNγ or TNFα for 16h. Total RNA was isolated and analyzed with reverse transcription 
and qPCR. Cyclophilin A was used as an endogenous control.  
 
The effects of IFNγ and TNFα on LCN2 expression are additive 
Next, we evaluated whether IFNγ and TNFα induced LCN2 expression by 
activating the same or different signaling pathways in adipocytes. Mature 3T3-L1 
adipocytes were treated for 16 hours and total RNA was isolated and analyzed by 
quantitative real-time PCR. As shown in Figure 2.4, TNFα is a more potent inducer of 
LCN2 mRNA than IFNγ. However, the presence of both IFNγ and TNFα always resulted 
in at least an additive effect on LCN2 expression. This additive effect is also observed 
with LCN2 protein expression and secretion (Figure 2.5). Collectively, these data 
indicate that IFNγ and TNFα affected LCN2 expression via stimulating different 
signaling pathways. 




                         
Figure 2.4. The effects of IFNγ and TNFα on LCN2 expression are additive. Mature 
3T3-L1 adipocytes were treated with 100ng/ml IFNγ or 0.5nM TNFα or both cytokines. 
RNA was isolated 16h later and subject to reverse transcription and qPCR.  
 
     
Figure 2.5. The effects of IFNγ and TNFα on LCN2 expression are additive. Whole cell 
extracts and media samples were collected after a 24h treatment. 250µg of protein from 






Identification of NF-κB and STAT1 binding sites in LCN2 promoter 
Since the induction of LCN2 expression by IFNγ or TNFα appeared to be 
mediated by different signaling pathways, we examined several signaling pathways 
known to mediate the effects of IFNγ and TNFα. We examined the role of STAT1, NF-
κB and ERK1/2 signaling pathways in the ability of IFNγ and TNFα to induce LCN2 
expression. First, we performed an analysis to search for potential STAT1 and NF-κB 
sites in the promoter of the murine LCN2 gene. Three potential NF-κB binding sites 
(Table 3) and nine potential STAT1 binding sites (Table 5) were identified by sequence 
analysis and experimentally examined by performing both electrophoretic mobility shift 
assays (EMSA) and chromatin immunoprecipitation (ChIP). Only one of the potential 
NF-κB binding sites was confirmed to interact with nuclear extracts from TNFα treated 
adipocytes and binding specificity was assessed by performing cold competition and 
generating a mutated binding site (Figure 2.6 and Table 4). An increase of cold 
competitor reduced the interaction between radioactively labeled probe and nuclear 
protein. A mutated probe (Table 4) did not associate with nuclear protein. A specific p65 
antibody was used to perform supershift analysis to determine whether NF-κB 
comprised the DNA binding complex. As indicated in Figure 2.7, pre-incubation with a 
p65 antibody resulted in a supershift of the TNFα induced binding, which suggests that 
the p65 component of NF-κB is present in the DNA-protein complex. Chromatin 
immunoprecipitation (ChIP) was also performed to examine the association of p65 with 
the murine LCN2 promoter. As shown in Figure 2.8, p65 bound to the murine LCN2 




Table 3. NF-κB binding sites in LCN2 promoter 





GGG NNN NNC C 
 
 
LCN2 -266 to -247 GC CCT GGG AAT GTC CCT CTG Yes Yes 
LCN2 -713 to -694 GG AGA GGG TGA GTC CCT GAG No No 
LCN2 -1795 to -1774 GAA CTT GGG GTC TCC CAT GTG C No No 
 
Table 4. Mutated NF-κB binding sites 
Gene Position Mutated sequence 
TNFα responsive 
(EMSA) 
LCN2 -266 to -247 GC CCT GAG AAT GTA CCT CTG No 
 
    
Figure 2.6. TNFα induces NF-κB binding to LCN2 promoter. Mature 3T3-L1 adipocytes 
were treated with 0.5 nM TNFα for 20min. Cytosolic and nuclear extracts were 
separated from treated or untreated mature adipocytes. 10μg of each extract was 
incubated with 50,000cpm/μl 32P-labeled double-stranded oligonucleotides of murine 
LCN2 promoter. Protein-DNA complexes were resolved by EMSA. Free probe was run 
out of the gel. The TNFα-responsive shift is indicated with an arrow (left panel). For cold 
competition, nuclear extracts were incubated with 50,000cpm/μl 32P-labeled probe and 
2μl unlabeled oligonucleotides of different concentrations (0.4μmol/L, 2μmol/L, 
10μmol/L) (middle panel). Nuclear extracts were also incubated with 50,000cpm/μl 32P-





Figure 2.7. TNFα induces NF-κB binding to LCN2 promoter. Cytosolic and nuclear 
extracts were prepared from mature adipocytes treated with TNFα for 20min. For 
supershift assay, the nuclear protein was pre-incubated with 1μg indicated antibody for 
1h, and then incubated with 32P-labeled probe and protein-DNA complexes were 
resolved by EMSA. 
 
                            
Figure 2.8. TNFα induces NF-κB binding to LCN2 promoter. 3T3-L1 adipocytes were 
treated or untreated with 0.5nM TNFα for 30min, and then cross-linked with 
formaldehyde. Chromatin extracts were prepared and subject to immunoprecipitation 
with IgG (Negative control) or p65 antibody. IP products were analyzed by qPCR. 





Nine potential STAT1 binding sites (Table 5) were experimentally examined by 
performing both EMSA and ChIP. EMSA analysis revealed that four of these sites 
interacted with nuclear protein from IFNγ treated adipocytes (Figure 2.9). Specificity 
was assessed by performing cold competition and generating mutated binding sites 
(data not shown) (Table 6). Supershift assay was performed with specific STATs 
antibodies to demonstrate whether these proteins were involved in the DNA binding 
complex. STAT1 was shown to bind to all four binding sites. To our surprise, STAT5A 
and STAT5B also interacted with -619, -1822 and -3171 binding sites (Figure 2.10). 
Since growth hormone (GH) is a physiological activator of STAT5A and STAT5B (99), 
we examined the ability of GH to regulate binding to these STAT sites. However, there 
was no association detected between labeled oligonucleotides and nuclear protein from 
GH treated adipocytes (data not shown). When we performed ChIP analysis to test 
these STAT binding sites, we confirmed the four binding sites that were validated by 
EMSA and observed STAT1 binding at one additional site (Table 5). Of note, this 
binding site at -1014 was not positive with nuclear protein in vitro, but was verified by 
ChIP using a STAT1 antibody (Figure 2.11). For all the five STAT1 binding sites, we did 
not observe any IFNγ induced interaction with STAT5 in vivo (data not shown).  
ERKs signaling modulates the ability of TNFα and IFNγ to induce LCN2 expression 
without having significant effects on STAT1 and NF-κB nuclear translocation or DNA 
binding activity 
Besides activating transcription factors like STAT1 and NF-κB, both IFNγ and 
TNFα acutely activate ERKs 1 and 2 (Figure 2.12). Mature adipocytes were pre-treated 
with UO126, a specific ERK inhibitor for 30 min and then nuclear translocation and 
tyrosine phosphorylation of STAT1 was examined after an IFNγ or TNFα treatment for 
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Table 5. STAT1 binding sites in LCN2 promoter 





TTC N2-4 GAA 
  
LCN2 -160 to -142 G TAT TTC AAC AGA ATG TAC No No 
LCN2 -619 to -602 GA CAC TTC CAG GAT AAT C Yes Yes 
LCN2 -676 to -657 GT CTG TTC CTG TAA ATG GCA Yes Yes 
LCN2 -705 to -688 GT GAG TCC CTG AGA GTT C No No 
LCN2 -1014 to -994 CCC ACT TTC CCC AAG GGC TCC No Yes 
LCN2 -1822 to -1806 GGT TGT TTC TTT GTA CT Yes Yes 
LCN2 -3132 to -3115 GGA TCC TTG AGA TGC AAC No No 
LCN2 -3159 to -3143 AG AGT TTC TGG ATC CGA No No 
LCN2 -3171 to -3152 CC AGT TTC TGG AAG AGT TTC Yes Yes 
 
Table 6. Mutated STAT1 binding sites 
Gene Position Mutated sequence 
IFNγ responsive 
(EMSA) 
LCN2 -619 to -602 GA CAC CTC CAG GCT AAT C No 
LCN2 -676 to -657 GT CTG TAC CTG TCA ATG GCA No 
LCN2 -1822 to -1806 GGT TGT CTC TTT GTC CT No 
LCn2 -3171 to -3152 CC AGT CTC TGG ACG AGT TTC No 
 
20 minutes. As shown in Figure 2.12, the IFNγ induced nuclear translocation and 
tyrosine phosphorylation of STAT1 was unaffected by ERKs inhibition. TNFα induced 
the nuclear translocation of p65 that was also unaffected by ERKs inhibition. The 
efficacy of ERKs inhibition is shown by using a phospho-specific antibody to assess 




Figure 2.9. IFNγ induces STAT1 binding to LCN2 promoter. Mature 3T3-L1 adipocytes 
were treated with 100ng/ml IFNγ for 20 min for the preparation of cytosolic and nuclear 
extracts. There was no binding in any cytosolic extracts (data not shown).  10μg of 
nuclear extract was incubated with 50,000cpm/μl 32P-labeled double-stranded 
oligonucleotides of murine LCN2 promoter. The protein-DNA complexes were resolved 




Figure 2.10. IFNγ induces STAT1 binding to LCN2 promoter. Nuclear extracts were 
prepared from mature adipocytes treated with IFNγ for 20 min. For super shift assay, 
the nuclear protein was pre-incubated with 1μg indicated antibody for 1h, and then 





Figure 2.11. IFNγ induces STAT1 binding to LCN2 promoter. 3T3-L1 adipocytes were 
treated or untreated with 100ng/ml IFNγ for 30min, and then cross-linked with 
formaldehyde. Chromatin extracts were prepared and subject to immunoprecipitation 
with IgG (Negative control) or the STAT1 antibodies indicated in the figure. IP products 
were analyzed by qPCR. Percentage of input was calculated and normalized to 
negative control. ***, P<0.01. 
 
of STAT5A. Although, ERKs inhibition did not affect the ability of these pro-inflammatory 
cytokine to induce nuclear translocation of STAT1 and p65, it did have substantial 
effects on the ability of these cytokines to induce LCN2 expression. As shown in Figure 
2.13, the induction of LCN2 mRNA levels by IFNγ and TNFα was repressed by ERKs 
inhibition. However, EMSA analysis revealed no alterations in binding to the NF-κB site 
in the LCN2 promoter in vitro (Figure 2.14) and ChIP analysis suggested that NF-κB 
binding to this site was not significantly altered in vivo (P=0.0538) (Figure 2.15). We 
also examined the STAT1 binding to the LCN2 promoter under conditions where ERKs 
were inhibited. As shown in Figure 2.16 and 2.17, there was no difference in binding in 
vitro or in vivo for any of the STAT1 binding sites identified. To determine if ERKs 
inhibition modulated LCN2 promoter activity in adipocytes, we cloned ~3.5 kb of the 
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murine LCN2 promoter into a pGL4.27 vector expressing firefly luciferase. This vector 
was transiently transfected into 3T3-L1 adipocytes. A Renilla-TK vector was co-
transfected to control for transfection efficiency. One day after transfection, the cells 
were treated with IFNγ or TNFα for 24h in the presence or absence of the ERK inhibitor. 
A dual-luciferase reporter assay was performed to quantitate the expression of 
luciferase. The results clearly showed that the ~3.5 kb segment, immediately upstream 
of the transcription start site within the LCN2 promoter was sensitive to both pro-
inflammatory cytokines. The promoter activity was highly similar to what we observed 
for the induction of LCN2 mRNA (refer to Figures 2.4 and 2.13). However, UO126 
pretreatment abrogated the stimulation of luciferase expression by both IFNγ and TNFα 
indicating that the inhibition of ERKs impaired the transcription activation activity of 
STAT1 and NF-κB (Figure 2.18). 
                     
Figure 2.12. ERK inhibition attenuates the ability of IFNγ and TNFα to induce LCN2 
without modulating the nuclear translocation or DNA binding activity of STAT1 and NF-
κB. Cytosolic and nuclear extracts were prepared from mature 3T3-L1 adipocytes 
treated or untreated with IFNγ or TNFα for 20min in the presence or absence of 50μM 




                      
Figure 2.13. ERKs inhibition attenuates the ability of IFNγ and TNFα to induce LCN2 
without modulating the nuclear translocation or DNA binding activity of STAT1 and NF-
κB. Mature 3T3-L1 adipocytes were pretreated with 50μM UO126 for 30min, and then 
treated with IFNγ or TNFα for 16h. Total RNA was isolated and analyzed with reverse 
transcription and qPCR. Cyclophilin A was used as endogenous control. ***, P<0.01. 
 
                                             
Figure 2.14. ERKs inhibition attenuates the ability of IFNγ and TNFα to induce LCN2 
without modulating the nuclear translocation or DNA binding activity of STAT1 and NF-
κB. Nuclear extracts were separated from adipocytes untreated or treated with TNFα for 
20 min in the presence or absence of UO126. 10μg of nuclear extract was incubated 
with 50,000cpm/μl 32P-labeled double-stranded oligonucleotides of murine LCN2 
promoter. Protein-DNA complexes were resolved by EMSA. 
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Figure 2.15. ERKs inhibition attenuates the ability of IFNγ and TNFα to induce LCN2 
without modulating the nuclear translocation or DNA binding activity of STAT1 and NF-
κB. 3T3-L1 adipocytes were untreated or exposed to TNFα for 30 min in the presence 
or absence of UO126, and then cross-linked with formaldehyde. Chromatin extracts 
were prepared and subject to immunoprecipitation with IgG (Negative control) or p65 
antibody. IP products were analyzed by qPCR. Percentage of input was calculated and 
normalized to negative control. ***, P<0.01. 
 
       
Figure 2.16. ERKs inhibition attenuates the ability of IFNγ and TNFα to induce LCN2 
without modulating the nuclear translocation or DNA binding activity of STAT1 and NF-
κB. Nuclear extracts were separated from untreated adipocytes or treated with IFNγ for 
20 min in the presence or absence of UO126. Protein-DNA complexes were resolved by 
EMSA as described above. 
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Figure 2.17. ERKs inhibition attenuates the ability of IFNγ and TNFα to induce LCN2 
without modulating the nuclear translocation or DNA binding activity of STAT1 and NF-
κB. 3T3-L1 adipocytes were untreated or exposed to IFNγ for 30min (-/+) UO126, and 
then cross-linked with formaldehyde. Chromatin IP experiments were performed with 
STAT 1 antibody for each of the LCN2 promoter sites indicated. ***, P<0.01. 
 
                   
Figure 2.18. ERKs inhibition impairs the induction of LCN2 promoter by both IFNγ and 
TNFα in adipocytes.  Mature 3T3-L1 adipocytes were transiently transfected with murine 
LCN2 promoter (-3358 to 112)/luciferase plasmid. A TK/renilla vector was used as 
control for transfection efficiency. After 24h post transfection, adipocytes were 
pretreated with 50 μM UO126 for 30 min and then stimulated with IFNγ or TNFα for 24 h. 
Relative light units (RLU) were calculated by dividing firefly luciferase activity by renilla 




IFNγ and TNFα induce LCN2 expression in human subcutaneous adipocytes 
An in silico analysis of the human LCN2 promoter revealed five potential STAT1 
binding sites at −856, −885, −1405, −1934, and −3610. As shown in Table 7, 
sequences of all these potential binding sites are largely conserved between mice and 
humans. Furthermore, the distribution of these sites in the human promoter is 
comparable with the STAT1 binding sites we characterized in the murine LCN2 
promoter. We also identified one potential NF-κB binding site in the human LCN2 
promoter at -176 and this is completely conserved between humans and mice (Table 7). 
Our in silico analysis of the human LCN2 promoter strongly suggests that STAT1 and 
NF-κB also mediate the induction of LCN2 expression in human adipocytes. In order to 
determine if the regulation we observed in murine 3T3-L1 adipocytes also occurred in 
human cells, we purchased human adipocytes. Human IFNγ and TNFα were used to 
treat human subcutaneous adipocytes for 24 h. As shown in Figure 2.19, the expression 
of LCN2 was up-regulated by both IFNγ and TNFα in human adipocytes. 
2.4 Discussions 
The endocrine properties of adipocytes are one of their most critical functions 
(138). Leptin and adiponectin are two hormones that are produced exclusively from 
adipocytes in mouse and man. Like LCN2, these hormones are also implicated in 
modulating insulin sensitivity and whole body energy balance (138). Although it is 
known that LCN2 expression can be highly induced and secreted from adipocytes and 
LCN2 is significantly regulated in conditions of mouse and human obesity, the 
mechanisms involved in this induction are poorly understood. LCN2 protein levels are  
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Figure 2.19. IFNγ and TNFα induce LCN2 expression in human adipocytes. Human 
subcutaneous adipocytes, purchased from Zenbio, were treated with 100 ng/ml IFNγ or 
0.5 nM TNFα. Whole cell extracts were harvested after 24h. Time 0 indicates no 
treatment. 150μg of whole cell extracts were subjected to western blot analysis. 300μg 
protein was used to perform immunoprecipitation with human LCN2 antibody. IP 
products were analyzed by western blot with human LCN2 antibody. 
 









-619 TTCCAGGATAAT -856 TTCAATGGAAAA 
-676 TTCCTGTAAA -885 TTCCAGAACC 
-1014 TTCAATTGAT -1405 TTCCTGGGAA 
-1822 TTCTTTGTAC -1934 TTCCCGAGTA 
-3171 TTCTGGAAGA -3610 TTCCTGAGATG 
NF-κB 
(GGGNNNNNCC) 




elevated in ob/ob mice and db/db mice (125), In agreement with these animal 
experiments, human studies revealed that circulating LCN2 concentrations positively 
correlate with adiposity, triglyceride concentration, blood glucose level and insulin 
resistance (126;127). Yet, LCN2 is negatively related to high-density lipoprotein 
cholesterol (127). However, there is very little information on the mechanisms involved 
in the modulation of LCN2 expression. It has been reported that Interleukin-1 beta (IL-
1β) induces LCN2 expression through NF-κB and JAK2 mediated signaling pathways 
(128). However, these observations are solely based on the use of inhibitors and no 
binding sites or promoter activity was examined. Other studies indicate that expression 
of LCN2 is up-regulated by agents that are associated with insulin resistance, including 
lipopolysaccharide (LPS) (129), glucocorticoid (130), and insulin (146). Insulin 
sensitizers, such as thiazolidinedione, down-regulate LCN2 expression (131). Our 
studies provide the first mechanistic data on the identification and binding of two 
transcription factors (STAT1 and NF-κB subunit p65) to the binding sites of the LCN2 
promoter in vitro and in vitro. These results also reveal a role of serine/threonine 
kinases ERKs 1 and 2 on the induction of LCN2 by pro-inflammatory cytokines that can 
be produced from immune cells in adipose tissue to inhibit insulin signaling and induce 
insulin resistance in adipocytes.  
Our studies demonstrate that IFNγ and TNFα, induce LCN2 expression in both 
murine and human adipocytes. We provide evidence that STAT1 plays a role in the 
effects of IFNγ, while TNFα induces LCN2 expression via NF-κB signaling pathways. 
Sequence analysis of the LCN2 promoter identified nine potential STAT binding sites 
and three potential NF-κB binding sites. Binding of these transcription factors was 
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assessed by both EMSA and ChIP analysis. These studies revealed the binding activity 
of a NF-κB site and five STAT1 binding sites in the LCN2 promoter. Transfection 
experiments with a promoter construct confirmed that the region containing these 
binding sites in LCN2 promoter mediated the increase of gene expression after IFNγ 
and TNFα treatment. Moreover, inhibition of ERKs 1 and 2 activation attenuated the 
stimulatory effects of both cytokines. Our data suggest that ERKs signaling is required 
for the maximal transactivation activity of STAT1 and NF-κB, but ERKs inhibition did not 
have a significant effect on nuclear localization or DNA binding activity of these 
transcription factors. Future studies will need to be performed to determine if ERKs 
have direct effects on the serine phosphorylation of p65 or STAT1. Previous studies 
have demonstrated that serine phosphorylation of STAT1 is required for its maximum 
transactivation activity (147). Also, several serine phosphorylation sites have been 
identified in NF-κB subunit p65 (148-152). Although our preliminary studies suggest 
these transcription factors are serine phosphorylated by ERKs, we have not examined 
whether this phosphorylation mediates the ERK-dependent effects on LCN2 expression. 
Collectively, our findings suggest that the ERKs signaling pathways crosstalk with the 
STAT1 and NF-κB signaling pathways in adipocytes.  
 One drawback related to our studies is that the functions of LCN2 still need to be 
determined. Although several groups have studied LCN2 null mice, the results of these 
studies are inconsistent. Previous research has shown important roles of LCN2 in the 
transportation of hydrophobic molecules, in limiting bacterial growth (119) and 
modulating degradation of the matrix turnover enzyme, MMP-9 (117). The versatile 
functions of LCN2 make it difficult to assess the primary reason that accounts for the 
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different phenotypes of the LCN2 null mice. Some data shows induction of PPARγ and 
adiponectin by LCN2 (131) suggesting that LCN2 may be beneficial. Yet, other studies 
indicate improved insulin action in LCN2 knockout cells (125), indicating that LCN2 is 
associated with metabolic dysfunction. Although it is clear that LCN2 affects adipocyte 
properties and participates in the regulation of insulin sensitivity, opposite effects of 
LCN2 have been reported. Therefore, our studies on the regulation of LCN2 expression 
have merit and allow us to speculate the inflammatory cytokines we have shown to 
induce LCN2 may play a role in metabolic dysfunction.  
In summary, LCN2 expression and secretion is induced by IFNγ and TNFα. Both 
of these pro-inflammatory cytokines are likely pathological mediators of increased LCN2 
expression that occurs in adipose tissue in conditions of insulin resistance in mouse and 
man. Our mechanistic studies reveal that STAT1, NF-κB and ERKs signaling pathways 
participate in the modulation of LCN2 expression in vitro and in vivo. Future studies will 









CHAPTER 3. THE INDUCTION OF LIPOCALIN-2 PROTEIN EXPRESSION IN VIVO 
AND IN VITRO 
 
3.1 Introduction 
Adipose tissue produces cytokines and hormones that modulate energy 
metabolism and systematic insulin sensitivity (138). Alterations in expression or 
secretion of these secreted proteins from adipocytes can contribute to insulin resistance. 
Chronic inflammation, accompanied by immune cell infiltration into adipose tissue, has 
been shown to play an important role in the pathogenesis of insulin resistance (1;16). 
Pro-inflammatory cytokines secreted by adipose tissue immune cells can affect 
properties of adipocytes. Two major pro-inflammatory cytokines, IFNγ and TNFα, can 
induce insulin resistance in adipocytes (15;33;44;140) and modulate the expression and 
secretion of adipokines (19;32;153), including adiponectin (19;22), which is exclusively 
expressed in mature adipocytes. 
Lipocalin-2 (LCN2) belongs to the lipocalin family, a group of well-known 
transporters of small hydrophobic molecules in circulation (116). LCN2 was initially 
characterized as protein that interacts with and stabilizes matrix metalloproteinase 9 
(117). LCN2 plays important roles in innate immune response by limiting bacterial 
growth (118;119;145). 
 
This chapter, THE INDUCTION OF LIPOCALIN-2 PROTEIN EXPRESSION IN VIVO AND IN VITRO, 
previously appeared as Zhao P, Elks CM and Stephens JM. The induction of lipocalin-2 protein 
expression in vivo and in vitro, J Biol Chem. 2014. It is reprinted by permission of the American Society 
for Biochemistry and Molecular Biology. 
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More recent studies have shown that LCN2 is a novel adipokine that is up-
regulated in obese and type 2 diabetic subjects (125). However, the roles of LCN2 in 
modulating insulin sensitivity are still unclear. Studies of global LCN2 knockout mice 
from separate groups have reported divergent phenotypes (132-134). Given the 
versatile functions of LCN2, it is not surprising that the phenotypes of global knockout 
mice are inconsistent. Although the role of LCN2 in modulation of insulin action is not 
clear, it is clear that LCN2 is produced in adipocytes and regulated in murine and 
human obesity (125-127). In one study, administration of LCN2 induced PPARγ and 
adiponectin expression and ameliorated the negative effects of TNFα in 3T3-L1 
adipocytes (131). Recently, LCN2 has been shown to be highly expressed in inguinal fat 
and to significantly affect HFD-induced adipose tissue expandability in a depot-specific 
manner (135). In this study, the absence of LCN2 expression significantly enhanced 
high fat diet (HFD)-induced inguinal fat expansion. Yet, compared to wild type mice, 
HFD-induced epididymal fat expansion in LCN2 deficient mice was significantly 
decreased (135). Although some observations suggest a potentially metabolically 
protective role of LCN2, there are substantial inconsistent observations related to 
actions of LCN2 in relation to glucose tolerance and insulin sensitivity (132-134).  
Despite the positive correlations of expression and circulating levels of LCN2 with 
obesity and insulin resistance (126;127), the underlying mechanism mediating the 
induction of LCN2 is still unknown. Here, we report that IFNγ and TNFα induce LCN2 
expression and secretion in vivo. Using knockdown methodology, we have shown that 
STAT1 and NF-κB are required for the induction of LCN2 by pro-inflammatory cytokines. 
Our previous observations demonstrated that ERKs signaling also contributes to the 
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IFNγ- and TNFα-induced expression of LCN2 (153). Our new results reveal that ERKs 1 
and 2 activation affects the serine phosphorylation of STAT1 and NF-κB at specific sites. 
These studies suggest that STAT 1 Ser727 phosphorylation plays a role in the additive 
effects of IFNγ and TNFα on LCN2 expression in adipocytes. Moreover, we have 
identified several STAT1 and NF-κB binding sites in the human LCN2 promoter, 
suggesting some translational relevance to our mechanistic studies. Collectively, our 
data demonstrates that IFNγ and TNFα are capable of inducing LCN2 from several 
insulin-sensitive tissues in vivo, and provides insight into the interplay between ERKs 
and STAT1 or NF-κB signaling pathways in adipocytes.  
3.2 Experimental Procedures 
Animal 
Procedures for animal studies were approved by the Pennington Biomedical 
Research Center Institutional Animal Care and Use Committee. Adult male C57BL/6J 
mice were purchased from The Jackson Laboratory. All mice were housed in groups of 
three or four, and had free access to water and standard chow (Purina LabDiet 5001). 
IFNγ and TNFα (R&D Systems) were dissolved in a sterile PBS with 0.1% BSA vehicle 
solution. 10-week old male mice (~25g) were injected intraperitoneally (i.p.) with 0.2 ml 
vehicle, IFNγ (1.25mg/kg body weight), TNFα (0.05mg/kg body weight), or both 
cytokines. Mice were euthanized by CO2 gas inhalation 3 hrs or 14 hrs post-injection. 
Tissues were removed, immediately frozen in liquid nitrogen, and stored at -80°C. Blood 
was collected into serum separator tubes, allowed to clot at room temperature, and 
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centrifuged at 1,500g for 15min at 4°C. The supernatant (serum) was then transferred to 
a clean tube and stored at -80°C for later analysis. 
Cell culture 
Murine 3T3-L1 preadipocytes were grown in Dulbecco’s Modified Eagle’s Media 
(DMEM) containing 10% bovine serum. Two days after confluence, 0.5 mmol/l 3-
isobutyl-methylxanthine, 1 μmol/l dexamethasone, and 1.7 μmol/l insulin (MDI) cocktail 
were added to induce preadipocytes differentiation in DMEM with 10% fetal bovine 
serum (FBS). Media was changed to DMEM with 10% FBS 48h later. DMEM was from 
Sigma. Bovine serum and FBS were from Hyclone. Human subcutaneous adipocytes in 
6-well plates were from Zen-Bio. Recombinant mouse and human IFNγ were purchased 
from R&D Systems. Recombinant mouse and human TNFα were purchased from Gibco. 
UO126 was purchased from Promega.  
Small interfering RNA-mediated knockdown 
3T3-L1 adipocytes were trypsinized and re-plated in 24-well plates. Cells were 
transfected using DharmaFECT Duo (Thermo-Dharmacon) reagent and 100nM siRNA 
(Thermo-Dharmacon). Non-targeting siRNA was used as negative control. After 24hrs, 
cells were harvested for RNA analysis and assessment of transfection efficiency.  
RNA analysis 
Tissues were homogenized in Trizol (Qiagen). Cell monolayers were harvested 
in RLT lysis buffer. Total RNA was isolated from homogenized tissues or harvested 
cells with a RNeasy mini kit (Qiagen). 10μl of purified RNA was used for reverse 
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transcription PCR to generate cDNA. Delta delta ct real-time PCR with SYBR supermix 
reagent (Takara) and an Applied Biosystems 7900HT system were used to analyze 
cDNA. Cyclophilin A was used as an endogenous control. The following primers were 
used for the real-time PCR: mCyclophilin A forward CCACTGTCGCTTTTCGCCGC and 
reverse TGCAAACAGCTCGAAGGAGACGC; mLCN2 forward TGCAAGTGGCCACCA 
CGGAG and reverse GCATTGGTCGGTGGGGACAGAGA. 
Preparation of whole cell extracts 
3T3-L1 adipocytes were harvested in non-denaturing IP buffer containing 
10 mmol/l Tris (pH 7.4), 150 mmol/l NaCl, 1 mmol/l EGTA, 1 mmol/l EDTA, 1% Triton X-
100, 0.5% Nonidet P-40, with protease inhibitors 1 μmol/l phenylmethylsulfonyl fluoride, 
1 μmol/l pepstatin, 50 mU trypsin inhibitory aprotinin, 10 μmol/l leupeptin, and 
phosphatase inhibitor 2 mmol/l sodium vanadate. Cell monolayers were scraped off the 
plates. Each extract was needled three times and centrifuged at 9500g for 10min at 4°C. 
Supernatants were then transferred to new tubes and analyzed with BCA (Pierce) to 
measure protein concentration. 
Gel electrophoresis and immunoblotting 
Proteins were separated on 7.5% or 10% gels by SDS-PAGE and transferred to 
nitrocellulose membranes. Membranes were blocked in 4% milk for 1h, and then 
incubated with primary antibody overnight at 4°C. After incubation with HRP-conjugated 
secondary antibodies (Jackson ImmunoResearch Laboratory), enhanced 
chemiluminescence reagents (Pierce) were used to visualize results. The LCN2 
antibody was purchased from R&D Systems. ERK1/2, STAT5A, p65Ser276 antibodies 
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were from Santa Cruz Technology. The adiponectin antibody was from Thermo-Pierce. 
STAT1, STAT1Tyr701, STAT1Ser727, STAT5, p65, p65Ser536, MCP-1 antibodies 
were from Cell Signaling Technology. The active ERK1/2 antibody was from Promega. 
Chromatin immunoprecipitation 
A SimpleChIP® Enzymatic Chromatin IP Kit (Cell Signaling Technology) was 
used for the ChIP assay. Human subcutaneous adipocytes were serum-deprived 
overnight. Cells were treated with recombinant human cytokines for 30min, and then 
cross-linked with formaldehyde and glycine. Chromatin extracts were prepared 
according to the manufacturer’s protocol. STAT1 and p65 antibodies for 
immunoprecipitation were purchased from Cell Signaling. Purified DNA was quantified 
by real-time PCR with SYBR green supermix and ROX buffer (Takara). Primer 
sequences for real-time PCR: -176 forward GAAACAGCACAAGGAAGGCACAGA and 
reverse CCTGCGGAAACACTTGGCAAGATT; -856 forward ATAACTGCTTCC 
CTGCTGGACAAG and reverse GGCCTTATCCTTGAGGTCACTGAG; -1405 forward 
CGGCCTGGCAGAGGATACTTTTTA and reverse GTTGCACCAAAGCCTTCCCTTTCT; 
-1934 forward GCCTCCCAGGTTCAAGCAATTCTT and reverse CAAAGATTAGTTG 
GGCATGGTGGC; -3610 forward CCACGCTGAACACTACTCACAAGA and reverse 
TGCATGAAGGCAGCAAGATGCTTC. Formula used to calculate percentage of input: 
Percentage of input=2%×2(C[T] 2% input sample−C[T] IP sample) 
Statistical analysis 
All data were analyzed by two-tailed unpaired Student’s t-test. Data of animal 
experiments are presented as mean±SEM. Results from studies of cultured adipocytes 
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are shown as mean±SD. Results were considered statistically significant when p<0.05 
(#, p<0.1; *, p<0.05; **, p<0.01; ***, p<0.001 vs. Control). 
3.3 Results 
LCN2 expression and secretion are induced by pro-inflammatory cytokines in vivo 
Several studies have shown that LCN2 is induced in obesity/T2DM (125-127) 
and we have shown that both IFNγ and TNFα induce LCN2 in cultured murine and 
human adipocytes (153).  However, the ability of these cytokines to induce LCN2 in the 
whole animal has not been investigated. To determine the ability of these cytokines to 
modulate LCN2 in vivo, 10-week old male C57BL/6J mice were injected i.p. with IFNγ or 
TNFα. After 14 hrs, the mice were sacrificed and epididymal fat pads were collected. As 
shown in Figures 3.1, both IFNγ and TNFα increase LCN2 mRNA levels in epididymal 
WAT. To determine if these cytokines could modulate circulating levels of LCN2, we 
also collected serum from these mice. As shown in Figure 3.2, IFNγ and TNFα 
increased circulating levels of LCN2.   
LCN2 is an adipokine, but is also known to be expressed in other tissues. 
Therefore, we examined the ability of IFNγ and TNFα to induce LCN2 expression in 
other insulin-sensitive tissues. In this experiment, C57BL/6J mice were injected i.p. with 
IFNγ, TNFα or both of these cytokines. Our previous studies demonstrated that IFNγ 
and TNFα had an additive effect on the induction of LCN2 in cultured adipocytes (153). 
As shown in Figure 3.3-3.7, IFNγ, TNFα and the combination of both cytokines 
treatments significantly induced LCN2 expression in epididymal WAT (Figure 3.3), liver 
(Figure 3.5) and heart (Figure 3.6) three hours after cytokine injection. The combination  
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Figure 3.1. IFNγ and TNFα induce LCN2 expression and secretion in vivo. 10-week old 
male C57BL/6J mice were injected i.p. with IFNγ (1.25 mg/kg body weight) or TNFα 
(0.05mg/kg body weight) and euthanized 14 hrs later. Total RNA in epididymal WAT 
was purified and analyzed by real-time PCR. Cyclophilin A was used as endogenous 
control. Data are shown as mean±SEM, n=4 mice/condition.*, p<0.05; **, p<0.01; ***, 
p<0.001. 
 
    
                       
Figure 3.2. IFNγ and TNFα induce LCN2 expression and secretion in vivo. 10-week old 
male C57BL/6J mice were injected i.p. with IFNγ (1.25 mg/kg body weight) or TNFα 
(0.05mg/kg body weight) and euthanized 14 hrs later. 250μg serum protein was 
subjected to western blot analysis. Western blot results were quantified with Image J.  
The quantification is in the bottom panel. Data are shown as mean±SEM, n=4 
mice/condition. *, p<0.05; **, p<0.01; ***, p<0.001. 
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of both cytokines caused a more robust elevation of LCN2 mRNA and provides novel 
data demonstrating that IFNγ and TNFα have additive effects on LCN2 expression in 
vivo. Treatment with either IFNγ or TNFα did not significantly induce LCN2 expression 
in inguinal WAT (Figure 3.4) or medial gastrocnemius (Figure 3.7). However, the 
combination treatment did significantly increase LCN2 in both of these tissues. As 
indicated in Table 8, epididymal WAT is the tissue that primarily responds to IFNγ 
treatment, as indicated by an increase in the LCN2 mRNA level of ~15-fold.  However, 
liver was the most sensitive to TNFα treatment and resulted in an elevation of LCN2 
mRNA levels by more than 2000-fold. Collectively, these experiments indicate that IFNγ 
and TNFα differentially modulate LCN2 expression in a tissue-specific manner and have 
additive effects in vivo.  
                         
Figure 3.3. IFNγ and TNFα differentially induce LCN2 expression in different tissues. 
10-week old male C57BL/6J mice were injected i.p. with IFNγ (1.25 mg/kg body weight), 
TNFα (0.05 mg/kg body weight), or both, and euthanized 3 hrs later. Total RNA in 
epididymal WAT was isolated and analyzed by real-time PCR. Cyclophilin A was used 
as endogenous control. Data are presented as mean±SEM, n=3 mice/condition. #, p<0.1; 




                   
Figure 3.4. IFNγ and TNFα differentially induce LCN2 expression in different tissues. 
10-week old male C57BL/6J mice were injected i.p. with IFNγ (1.25 mg/kg body weight), 
TNFα (0.05 mg/kg body weight), or both, and euthanized 3 hrs later. Total RNA in 
inguinal WAT was isolated and analyzed by real-time PCR. Cyclophilin A was used as 
endogenous control. Data are presented as mean±SEM, n=3 mice/condition. #, p<0.1; *, 
p<0.05; **, p<0.01; ***, p<0.001. 
 
     
Figure 3.5. IFNγ and TNFα differentially induce LCN2 expression in different tissues. 
10-week old male C57BL/6J mice were injected i.p. with IFNγ (1.25 mg/kg body weight), 
TNFα (0.05 mg/kg body weight), or both, and euthanized 3 hrs later. Total RNA in liver 
was isolated and analyzed by real-time PCR. Cyclophilin A was used as endogenous 
control. Data are presented as mean±SEM, n=3 mice/condition. #, p<0.1; *, p<0.05; **, 
p<0.01; ***, p<0.001. 
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Figure 3.6. IFNγ and TNFα differentially induce LCN2 expression in different tissues. 
10-week old male C57BL/6J mice were injected i.p. with IFNγ (1.25 mg/kg body weight), 
TNFα (0.05 mg/kg body weight), or both, and euthanized 3 hrs later. Total RNA in heart 
was isolated and analyzed by real-time PCR. Cyclophilin A was used as endogenous 
control. Data are presented as mean±SEM, n=3 mice/condition. #, p<0.1; *, p<0.05; **, 
p<0.01; ***, p<0.001. 
 
                       
Figure 3.7. IFNγ and TNFα differentially induce LCN2 expression in different tissues. 
10-week old male C57BL/6J mice were injected i.p. with IFNγ (1.25 mg/kg body weight), 
TNFα (0.05 mg/kg body weight), or both, and euthanized 3 hrs later. Total RNA in 
gastrocnemius was isolated and analyzed by real-time PCR. Cyclophilin A was used as 
endogenous control. Data are presented as mean±SEM, n=3 mice/condition. #, p<0.1; *, 




Table 8. IFNγ and TNFα-induced LCN2 expression in different tissues  
 IFNγ TNFα IFNγ+TNFα 
Epididymal WAT 17-fold** 26-fold** 86-fold*** 
Inguinal WAT n.s. n.s.#(P=0.0875) 44-fold** 
Liver 7-fold* 2175-fold* 4527-fold** 
Heart 3-fold* 14-fold*** 67-fold*** 
Gastrocnemius n.s. n.s. 9-fold** 
( n.s., not significant; #, p<0.1; *, p<0.05; **, p<0.01; ***, p<0.001. ) 
 
NF-κB is required for TNFα induced LCN2 expression  
Recent studies by our laboratory have shown that TNFα-induced NF-κB 
activation results in binding of p65 to one site in the murine LCN2 promoter and 
correlates with the induction of LCN2 expression (153). To determine the importance of 
NF-κB signaling in the ability of TNFα to induce LCN2 expression in adipocytes we used 
a knockdown approach. Small interfering-RNA targeting the p65 subunit of NF-κB was 
transfected into mature 3T3-L1 adipocytes. As shown in Figure 3.8, p65 mRNA levels 
were reduced by 60~70 percent with p65 siRNA transfection. Non-targeting siRNA was 
used as negative control and had no effect on p65 mRNA expression. Two days after 
transfection, adipocytes were serum-deprived overnight and then treated with TNFα for 
16 hrs (for RNA analysis) or 24 hrs (for protein analysis). As expected, TNFα induced 
LCN2 mRNA and protein in control adipocytes and in adipocytes transfected with non-
targeting siRNA. However, the ability of TNFα to induce LCN2 mRNA (Figure 3.9) and 
protein (Figure 3.10) was substantially reduced in cells transfected with p65 siRNA. 
STAT5A was used as a protein loading control. We also examined the expression level 
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of MCP-1, an inflammatory marker that can be induced by TNFα and secreted by 
adipocytes. The TNFα mediated induce of MCP-1 was also substantially decreased by 
p65 knockdown.  
                              
Figure 3.8. NF-κB is required for TNFα-induced LCN2 expression in adipocytes. 3T3-L1 
adipocytes were transfected with 100nM non-targeting siRNA or p65 siRNA. 24 hrs later, 
total RNA was purified and analyzed by real-time PCR. Cyclophilin A was used as 
endogenous control. ***, p<0.001. 
 
                                
Figure 3.9. NF-κB is required for TNFα-induced LCN2 expression in adipocytes. 3T3-L1 
adipocytes were transfected with 100nM non-targeting siRNA or p65 siRNA. After 40hrs, 
cells were serum-deprived for 24hrs, and treated with 0.5nM TNFα. Total RNA was 
isolated 16hrs later, and subjected to quantitative real-time PCR. Cyclophilin A was 
used as endogenous control. ***, p<0.001. 
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Figure 3.10. NF-κB is required for TNFα-induced LCN2 expression in adipocytes. 3T3-
L1 adipocytes were transfected with 100nM non-targeting siRNA or p65 siRNA. 40hrs 
after transfection, adipocytes were serum-deprived for 24hrs, and treated with 0.5nM 
TNFα. Whole cell extract was harvested after 24hrs. 150 μg protein was analyzed by 
western blot.  
 
STAT1 is required for IFNγ induced LCN2 expression  
Our recent studies have also shown that IFNγ-induced LCN2 expression 
correlates with the binding of STAT1 to five sites in the murine LCN2 promoter (153). To 
determine if IFNγ-activated STAT1 was required for the induction of LCN2 in adipocytes, 
we used a siRNA knockdown approach. STAT1 mRNA was decreased by ~60 percent 
with STAT1 knockdown (Figure 3.11). Transfection of non-targeting siRNA had no effect 
on STAT1 mRNA level. Two days after transfection, mature adipocytes were serum 
deprived and treated with IFNγ for 16 hrs (for RNA analysis) or 24 hrs (for protein 
analysis). As previously reported, IFNγ treatment induced LCN2 mRNA (Figure 3.12) 
and protein levels (Figure 3.13) in 3T3-L1 adipocytes. Moreover, the induction of LCN2 
was significantly reduced in adipocytes that had less STAT1. STAT1 knockdown had no 
effect on STAT5 proteins in adipocytes (Figure 3.13). It is known that IFNγ can induce 
59 
 
MCP-1 in human mesangial cells (154); we observed a similar induction of MCP-1 in 
3T3-L1 adipocytes following IFNγ treatment. However, STAT1 knockdown did not affect 
IFNγ-induced MCP-1 expression.   
                       
Figure 3.11. STAT1 is necessary for IFNγ-induced LCN2 expression in adipocytes. 3T3-
L1 adipocytes were transfected with 100nM STAT1 siRNA or non-targeting siRNA. 
24hrs later, total RNA was purified and analyzed by real-time PCR. Cyclophilin A was 
used as endogenous control. ***, p<0.001. 
 
                        
Figure 3.12. STAT1 is necessary for IFNγ-induced LCN2 expression in adipocytes. 3T3-
L1 adipocytes were transfected with 100nM STAT1 siRNA or non-targeting siRNA. After 
40hrs, cells were serum-deprived for 24hrs, and treated with 100ng/ml IFNγ. Total RNA 
was isolated 16hrs later, and subjected to quantitative real-time PCR. Cyclophilin A was 
used as endogenous control. ***, p<0.001. 
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Figure 3.13. STAT1 is necessary for IFNγ-induced LCN2 expression in adipocytes. 3T3-
L1 adipocytes were transfected with 100nM STAT1 siRNA or non-targeting siRNA. 
40hrs after transfection, adipocytes were serum-deprived for 24hrs, and treated with 
100ng/ml IFNγ. Whole cell extracts were obtained after 24 hrs and 150 μg protein was 
analyzed by western blot. ***, p<0.001. 
 
TNFα- and IFNγ-induced ERKs signaling modulates the serine phosphorylation of 
STAT1 and p65 
Our recent studies on LCN2 have shown that the induction of this adipokine by 
both IFNγ and TNFα is dependent on ERKs activation (153). Hence, we wanted to 
investigate how ERKs signaling contributes to the effects of these cytokines. There is 
evidence to suggest that serine phosphorylation of NF-κB (148;150;155) and STAT1 
(147;156) plays a role in transcriptional activity of these signaling proteins. Therefore, 
we examined the phosphorylation of STAT1 at Ser727 and p65 at Ser536 to determine the 
effects of IFNγ or TNFα treatment on phosphorylation. Fully differentiated 3T3-L1 
adipocytes were acutely treated (15 min.) with IFNγ, TNFα or both cytokines. As shown 
in Figure 3.14, IFNγ and TNFα activate the ERKs 1 and 2 signaling pathways in 
adipocytes. Of note, TNFα treatment in the presence or absence of IFNγ induced 
phosphorylation of Ser536 on p65. However, IFNγ did not modulate p65 serine 
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phosphorylation at this site. IFNγ did induce STAT1 tyrosine phosphorylation. All 
treatments induced STAT1 Ser727 phosphorylation. The data clearly indicate an additive 
effect of IFNγ and TNFα on STAT1Ser727 phosphorylation.  
                          
Figure 3.14. Regulation of the ERKs signaling pathway and STAT1 and NF-κB serine 
phosphorylation by IFNγ and TNFα. Mature adipocytes were treated with IFNγ 
(100ng/ml), TNFα (0.5nM) or combo for 15min. Whole cell extracts were prepared and 
150 μg protein was subjected to western blot analysis.  
 
NF-κB signaling studies have also revealed that p65 can be phosphorylated on 
Ser276 by activation of PKA (155). Therefore, we also examined p65 Ser276 
phosphorylation. Forskolin, a PKA activator, was used as a positive control in these 
experiments. As shown in Figure 3.15, neither IFNγ nor TNFα had effect on p65Ser276. 
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Nonetheless, we examined the ability of p65 Ser276 phosphorylation to influence LCN2 
expression. Mature adipocytes were treated with TNFα or forskolin for 16 hrs. TNFα 
induced LCN2 expression, whereas forskolin decreased LCN2 expression (Figure 3.16). 
These results suggest that phosphorylation of p65 Ser276 does not participate in the 
induction of LCN2 expression. 
               
Figure 3.15. Regulation of the ERKs signaling pathway and STAT1 and NF-κB serine 
phosphorylation by IFNγ and TNFα. Cells were treated with IFNγ (100ng/ml), TNFα 
(0.5nM) or forskolin (20μM) for 15min. Whole cell extracts were harvested, and 150 μg 
protein was analyzed by western blot.  
 
                                
Figure 3.16. Regulation of the ERKs signaling pathway and STAT1 and NF-κB serine 
phosphorylation by IFNγ and TNFα. 3T3-L1 adipocytes were treated with TNFα (0.5nM) 
or forskolin (20μM) for 16hrs. Total RNA was isolated and subjected to real-time PCR 
analysis. Cyclophilin A was used as endogenous control. These data are from 




Since our results suggested that serine phosphorylation may play a role in the 
additive effects of TNFα or IFNγ on LCN2 expression, we assessed whether the 
activation of ERKs was required for serine phosphorylation of p65 and STAT1. Mature 
3T3-L1 adipocytes were pretreated with the highly specific ERK inhibitor UO126 for 30 
min and then exposed to TNFα or IFNγ for an additional 15 min. As expected, ERKs 
activation was inhibited by UO126 pretreatment. We observed that TNFα-induced p65 
Ser536 phosphorylation was eliminated by inhibition of ERKs (Figure 3.17). This data 
suggests that ERKs directly mediate Ser536 phosphorylation of p65. Although UO126 
pretreatment had no effect on IFNγ-induced STAT1 tyrosine phosphorylation, both 
IFNγ- and TNFα-induced serine phosphorylation of STAT1 were abolished by ERKs 
inhibition (Figure 3.18).  
                           
Figure 3.17. Activation of ERKs is required for serine phosphorylation of NF-κB 
p65Ser536 and STAT1Ser727. 3T3-L1 adipocytes were pretreated with 50μM ERKs 
inhibitor UO126 for 30min, and then treated with 0.5nM TNFα for 15min. Whole cell 




                        
Figure 3.18. Activation of ERKs is required for serine phosphorylation of NF-κB 
p65Ser536 and STAT1Ser727. Adipocytes were treated with 100ng/ml IFNγ or 0.5nM 
TNFα in presence or absence of 50μM UO126. Whole cell extracts were harvested and 
150 μg protein was subjected to western blot analysis.  
 
Identification of STAT1 and NF-κB binding sites in human LCN2 promoter 
As indicated above, our recent efforts have identified one NF-κB and several 
STAT1 binding sites in the murine LCN2 promoter (153). Hence, we performed an in 
silico analysis to identify potential STAT1 and NF-κB binding sites in human LCN2 
promoter (Table 9). The four potential STAT1 binding sites and one potential NF-κB 
binding site were examined by ChIP assays. Human subcutaneous adipocytes were 
treated with recombinant human IFNγ or TNFα for 30 min. ChIP assays were performed 
with specific STAT1 and p65 antibodies. As shown in Figure 3.19, we observed that all 
four potential STAT binding sites were capable of interacting with STAT1 in an IFNγ-
induced manner in human fat cells in vivo. In addition, we observed TNFα-induced p65 
binding to a NF-κB binding site in the human LCN2 promoter in human adipocytes 



















                 
Figure 3.19. Identification of STAT1 binding sites in the human LCN2 promoter. Human 
subcutaneous adipocytes were treated or untreated with 100ng/ml recombinant human 
IFNγ for 30 min, and then cross-linked with formaldehyde. Chromatin extracts were 
prepared and immunoprecipitated with STAT1 antibody. IP products were subjected to 
quantitative real-time PCR analysis. Percentage of input was calculated and normalized 




                                
Figure 3.20. Identification of an NF-κB binding site in the human LCN2 promoter. 
Human subcutaneous adipocytes were untreated or treated with 0.5nM recombinant 
human TNFα for 30min, and cross-linked with formaldehyde. Chromatin extracts were 
isolated and subjected to immunoprecipitation with NF-κB p65 antibody. IP products 
were analyzed by real-time PCR. Percentage of input was calculated and normalized to 
the control. ***, p<0.001. 
 
3.4 Discussions  
Chronic inflammation in adipose tissue is associated with insulin resistance 
(1;16). Pro-inflammatory cytokines secreted by immune cells that are present in adipose 
tissue can affect the functions of adipocytes, including insulin sensitivity and endocrine 
functions. The adipokine LCN2 is significantly elevated in obese and diabetic subjects 
(126;127) and studies in animal models demonstrate increased LCN2 in the adipose 
tissue of ob/ob and db/db mice (125). Despite the profound induction of LCN2 in obesity 
in mice and man, the underlying mechanisms mediating these effects are largely 
unknown. Our studies show that IFNγ and TNFα are able to induce LCN2 expression in 
vitro (153) and we have now demonstrated profound modulation of LCN2 in vivo. We 
observed that IFNγ and TNFα induced LCN2 in the primary insulin sensitive tissues: 
adipose tissue, skeletal muscle and liver. These studies also provide the first in vivo 
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evidence to support the hypothesis that immune cell-derived inflammatory cytokines 
may be responsible for the increase of LCN2 expression in obesity and type 2 diabetes. 
Our studies also reveal tissue specific responses. IFNγ treatment affected LCN2 
expression primarily in epididymal WAT, whereas LCN2 modulation in liver was most 
sensitive to TNFα. We did not observe a significant increase of LCN2 in inguinal WAT or 
gastrocnemius in mice treated with IFNγ or TNFα. However, there was a significant 
cooperative effect of IFNγ and TNFα on LCN2 induction in most tissues examined. 
These are the first studies to demonstrate such an effect in vivo. In our studies, we 
delivered cytokines via i.p. injection. Since inguinal WAT and gastrocnemius are not in 
the abdominal cavity, the lack of response in these tissues could be due to their 
physical distance from the injection site, which may lead to limited responsiveness to 
this specific method of cytokine treatment. It is possible that intravenous administration 
of the cytokines could produce different responses in these two tissues. 
Our previous studies suggested that STAT1 mediates IFNγ-induced LCN2 
expression and that NF-κB plays a role in TNFα-mediated induction of LCN2 in cultured 
adipocytes (153).  However, both of these cytokines activate other signaling pathways, 
so we investigated the dependence of STAT1 or the p65 subunit of NF-κB by 
performing siRNA-mediated knockdown of these two transcription factors. Our results 
demonstrated that STAT1 knockdown significantly attenuates IFNγ-induced LCN2 
expression, while p65 knockdown ameliorates the induction effects of TNFα. These 
observations demonstrate that IFNγ-induced LCN2 expression is largely mediated by 
STAT1 and that TNFα requires NF-κB to induce LCN2 expression in adipocytes. There 
is some additional specificity in our observations as the knockdown of p65 also inhibited 
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TNFα-induced MCP-1 expression, but STAT1 knockdown did not affect the ability of 
IFNγ to induce MCP-1. It is not surprising that loss of STAT1 or p65 does not 
completely abolish the induction of LCN2 expression since siRNA-mediated knockdown 
of these transcription factors reduced, but did not abolish, their expression levels. 
Although LCN2 expression is likely affected by other transcription factors, our 
observations strongly suggest that STAT1 and p65 are critical for the induction of LCN2 
by IFNγ and TNFα. 
Our previous studies on LCN2 revealed that ERKs 1 and 2 signaling was 
required for the induction of LCN2 expression by IFNγ and TNFα  in adipocytes (153). 
To follow up on these studies, we examined serine phosphorylation of STAT1 and the 
p65 subunit of NF-κB.  Some studies suggest that STAT1Ser727 phosphorylation 
contributes to the maximal transactivation activity of STAT1 (147). The NF-κB p65 
subunit can be phosphorylated at Ser276 (152;155) and Ser536 (148;150). However, the 
functions of these phosphorylated serines are controversial. ERKs 1 and 2 are 
serine/threonine kinases activated by both IFNγ (142) and TNFα (144). We 
hypothesized that IFNγ- and TNFα-induced activation of ERKs may contribute to the 
serine phosphorylation of both STAT1 and NF-κB in adipocytes. Our results clearly 
show that phosphorylation of STAT1 Ser727 and p65Ser536 are mediated by activation of 
ERKs 1 and 2. However, neither IFNγ nor TNFα treatment affected phosphorylation of 
p65Ser276. As expected, the PKA activator forskolin induced p65Ser276 phosphorylation, 
but it did not increase LCN2 expression. Forskolin treatment decreased LCN2 
expression in adipocytes. These results indicate that p65Ser276 phosphorylation does 
not participate in the profound stimulatory effects of IFNγ and TNFα on LCN2 
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expression in adipocytes. The phosphorylation of p65Ser536 is induced by TNFα, but not 
enhanced in the presence of IFNγ. However, STAT1Ser727 phosphorylation is much 
greater in the presence of IFNγ and TNFα when compared to individual cytokine 
treatments. Our study also supports data that IFNγ-induced STAT1 serine 
phosphorylation is not dependent on tyrosine phosphorylation (157). Although we 
observed TNFα-induced STAT1Ser727 phosphorylation, we did not observe any effect 
on STAT1 tyrosine phosphorylation under these conditions. There is no doubt that the 
combination of IFNγ and TNFα had a cooperative effect on STAT1Ser727 
phosphorylation and LCN2 expression. Although TNFα does not result in the tyrosine 
phosphorylation of STAT1, our results strongly suggest that TNFα-induces ERKs 1 and 
2 phosphorylation of STAT1Ser727 that mediates a cooperative effect between IFNγ or 
TNFα on LCN2 gene expression. It should be noted that these cytokines can modulate 
other signaling proteins and the cooperative effects on LCN2 expression may be 
influenced by ERK-independent pathways or other phosphorylation events. However, 
based on our previous studies on LCN2 (153) and our current results, we propose that 
STAT1Ser727 mediates cytokine cooperativity and that there is minimal contribution from 
other signaling pathways in the regulation of LCN2 in fat cells.   
In summary, our study shows that the pro-inflammatory cytokines IFNγ and TNFα 
induce LCN2 expression and secretion in vivo. The presence of both cytokines results 
in an additive effect on LCN2 expression. STAT1 is required for IFNγ-induced LCN2 
expression, while NF-κB is necessary for the induction of both LCN2 and MCP-1 by 
TNFα. ERKs signaling appears to contribute to the stimulatory effects of IFNγ and TNFα 
via modulating serine phosphorylation of STAT1 and the p65 subunit of NF-κB. Four 
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STAT1 binding sites and one NF-κB binding site were also identified in the human 
LCN2 promoter, which suggests that our observations have translational relevance.  
These studies provide insight into the ability of pro-inflammatory cytokines to regulate 
adipocyte function. Although the roles of LCN2 in insulin resistance are still unclear, our 
mechanistic studies on LCN2 expression do increase our understanding of the 















CHAPTER 4. SUMMARY AND FUTURE PLAN 
4.1 Research Summary 
Several studies in the last decade have shown that expression and secretion of 
LCN2 is significantly up-regulated in obesity and insulin resistance in mice and man 
(125-127). However, the mechanisms underlying how LCN2 expression is modulated 
under these conditions are largely unknown. Our studies report that two pro-
inflammatory cytokines induce LCN2 expression and secretion in cultured mouse and 
human adipocytes. The induction of LCN2 is decreased by the inhibition of transcription 
by actinomycin D. In mice, an intraperitoneal injection of IFNγ or TNFα induces LCN2 
expression in multiple insulin sensitive tissues and increases circulating levels of LCN2. 
The 2000-fold induction of LCN2 by TNFα in the liver did suggest that liver-secreted 
LCN2 is likely responsible for its primary endocrine activities while LCN2 from adipose 
tissue may be limited to paracrine functions. For both in vivo and in vitro experiments, 
we observed an additive effect of IFNγ and TNFα on LCN2 expression. Our in vitro 
signaling experiments have revealed that STAT1 and ERKs signaling pathways are 
required for the induction of LCN2 expression by IFNγ. Our studies have also shown 
that modulation of LCN2 by TNFα requires NF-κB and ERKs signaling pathways. 
SiRNA-mediated knockdown of STAT1 attenuates IFNγ-induced elevation of LCN2 
expression in adipocytes. Similarly, knockdown of NF-κB subunit p65 significantly 
ameliorates the increase of LCN2 expression by TNFα. The inhibition of ERKs using the 
pharmacological inhibitor UO126 ameliorates the induction effects of both IFNγ and 
TNFα. These observations suggest that ERKs signaling also contributes to the induction 
of LCN2 expression. Studies by other labs have shown that serine phosphorylation can 
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affect the transcriptional activation activity of STAT1 (147) and NF-κB (148;152;155). 
Serine727 is located in the TAD of STAT1 (158). A STAT1 S727A mutant has reduced 
association with co-activator CREB-binding protein (CBP) (156). Similar to STAT1, 
Serine536 is located in the TAD of p65. Phosphorylation of p65 Ser536 mediates its 
association with CBP and dissociation with HDAC1 and 3 (148). Also, unphosphorylated 
Ser536 and Asp533 can form a hydrogen bond, which is required for the interaction 
between corepressor amino-terminal enhancer of split (AES) and p65 TAD (159). 
Hence, we determined if active ERKs regulated the serine phosphorylation of STAT1 
and p65 in adipocytes and/or the ability to modulate LCN2 expression. Our observations 
clearly showed that activation of ERKs signaling is responsible for IFNγ and TNFα-
induced serine phosphorylation of STAT1 and p65, respectively. IFNγ and TNFα also 
have an additive effect on the serine phosphorylation of STAT1 and these data suggest 
that this covalent modification may play a role in the additive effects of the pro-
inflammatory cytokines on LCN2 expression. 
Our in silico analysis of the LCN2 promoter revealed several potential STAT1 
and NF-κB binding sites in the murine LCN2 promoter. By examining the interaction 
between transcription factors and potential DNA binding sites with both electrophoretic 
mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP), we confirmed 
five STAT1 binding sites and one NF-κB binding site in the murine LCN2 promoter. 
Pretreatment with an ERKs inhibitor showed no significant effects on either nuclear 
translocation or DNA binding activity of either STAT1 or NF-κB. Our transfection studies 
in 3T3-L1 adipocytes with plasmids containing the murine LCN2 promoter confirmed 
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that inhibition of ERKs activation ameliorated the transcriptional activity of both STAT1 
and NF-κB.  
In order to determine if pro-inflammatory cytokines also induced LCN2 
expression in humans, we used human subcutaneous adipocytes that we treated with 
IFNγ or TNFα. Similar to our observations in murine fat cells, our results demonstrated 
that both IFNγ and TNFα induced LCN2 expression in human adipocytes. Additional in 
silico analyses revealed several potential STAT1 binding sites and NF-κB binding site in 
the human LCN2 promoter. We confirmed all these DNA binding sites by performing by 
ChIP analysis in human subcutaneous adipocytes. We also noted conservation of the 
STAT1 binding sites between mice and humans. However, the NF-κB binding site was 
completely conserved between mice and humans.  
4.2 Significance of Research 
Chronic inflammation has been shown to contribute to the pathogenesis of insulin 
resistance. The pro-inflammatory cytokines produced from immune cells in adipose 
tissues significantly affect the properties of adipocytes. LCN2 is a relatively new 
adipokine that is highly expressed in adipocytes and significantly induced in obesity and 
insulin resistance. However, the mechanisms involved in the modulation of LCN2 
expression in pathological conditions were largely unknown. Our studies revealed that 
LCN2 expression is modulated by IFNγ and TNFα, two important pro-inflammatory 
cytokines and inducers of insulin resistance. Although the role of adipose tissue-derived 
LCN2 in insulin resistance is still not clear, several studies have demonstrated that 
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LCN2 affects functions of adipocytes and adipose tissue. Our observations increase the 
knowledge of LCN2 expression in obese and insulin resistant subjects.  
STAT1 and ERKs signaling pathways are utilized by IFNγ, and NF-κB and ERKs 
pathways are adopted by TNFα in mature adipocytes to regulate LCN2 expression. 
ERK signaling mediates the serine phosphorylation of STAT1 and NF-κB to regulate the 
transactivation activity of both these transcription factors. These studies provide insight 
regarding three distinct signaling pathways that are utilized by two important pro-
inflammatory cytokines in mature adipocytes. These results enhance our understanding 
about how chronic inflammation and pro-inflammatory cytokines modulate the function 
and gene expression of adipocytes in conditions of metabolic dysfunction.  
4.3 Future Plans 
The primary limitation to our studies on LCN2 is that we do not fully understand 
the role of LCN2 in the pathogenesis of insulin resistance. Previous studies of LCN2 
global knockout mice showed completely different phenotypes (132-134), which further 
contributes to our lack of understanding of LCN2 function. However, the reported 
functions of LCN2 are highly versatile, a fact that likely accounts for the diverse 
phenotypes of global knockout mice. According to unpublished data from Ronald Kahn’s 
lab, the microbiota of mice is significantly changed when the animals are kept at 
different facilities. There is mounting evidence to suggest that the variation of microbiota 
could result in distinct phenotypes, even for mice that are genetically identical. 
Considering the functions of LCN2 in limiting bacterial growth (118;119), global 
knockout of LCN2 could exacerbate the variance of microbiota and significantly 
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contribute to the different phenotypes of LCN2 null mice that have been observed by 
different laboratories. In addition, diet is a critical contributor to microbiota populations 
(160;161). Hence, differences in the phenotypes of these animals could also be due to 
different diets that impact microbiota.   
Since the production of LCN2 significantly increases in insulin-resistant subjects, 
future studies should focus on trying to determine the function of LCN2 produced by 
adipocytes and adipose tissues. Studies have shown that expression of PPARγ and 
adiponectin are elevated by LCN2 treatment (131). Recent publications have also 
reported that LCN2 positively modulates fatty acid oxidation and energy expenditure 
(136). Both of these studies suggest a protective role of LCN2 against obesity and 
insulin resistance. Although we demonstrated that LCN2 expression is highly induced 
by pro-inflammatory cytokines, it is possible that LCN2 mediates a negative feedback to 
counteract the effects of pro-inflammatory cytokines on adipocytes. It would be 
interesting to determine if LCN2 pretreatment can attenuate the impact of pro-
inflammatory cytokine-activated signaling in mature adipocytes. Since LCN2 is 
produced in several cell types, it would be important to assess the role of adipocyte-
derived LCN2. This could be achieved by making an adipocyte-specific knockout of 
LCN2 in mice and studying the mice in diabetic conditions.  
It is known that LCN2 interacts with MMP-9, an important gelatinase that can 
degrade elastin in matrix (162). Previous research has revealed that MMP-9 is also 
increased in obese subjects (163). A recent study has also shown that elastin-derived 
peptides, which are generated from the degradation of matrix elastin, have the 
capability to modulate insulin sensitivity (164). Considering all this data, it would be 
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logical to examine the possibility that LCN2 affects insulin sensitivity via regulating 
matrix turnover. Future studies on LCN2 should focus on elucidating the functions of 
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